

AS

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 January 2001 (18.01.2001)

PCT

(10) International Publication Number
WO 01/03681 A2

(51) International Patent Classification⁷: **A61K 31/00**

(21) International Application Number: **PCT/IB00/01039**

(22) International Filing Date: **7 July 2000 (07.07.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/142,894 8 July 1999 (08.07.1999) US
60/163,089 2 November 1999 (02.11.1999) US

(71) Applicant and

(72) Inventor: **PRENDERGAST, Patrick, T.** [IE/IE]; Bay-
bush, Straffan, County Kildare (IE).

(74) Agent: **TAUCHNER, Paul**; Vossius & Partner, Siebert-
strasse 4, D-81675 München (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AT
(utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA,

CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility
model), DK, DK (utility model), DM, DZ, EE, EE (utility
model), ES, FI, FI (utility model), GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (utility
model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,
MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT,
TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— Without international search report and to be republished
upon receipt of that report.

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: **USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS**

(57) Abstract: The invention provides the use of flavin compounds such as cirsiolol, 3',4'-diacetoxy-5,6,7-trimethoxyflavone or naringin in the treatment of infections, particularly for viral (e.g., HCV, HIV, a picornavirus genus virus or a respiratory virus) or parasite (e.g., toxoplasmosis) infections. Also provided are compositions for use in the methods.

WO 01/03681 A2

USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS

BACKGROUND OF THE INVENTION

5 The present invention is directed to the use of flavones, flavanones and related compounds, to treat infectious conditions such as viral or parasite infections.

 The common cold and other respiratory infections are often associated with or caused by infection by a number of viruses that can infect the respiratory system
10 ("respiratory viruses"), such as rhinoviruses, paramyxoviruses such as respiratory syncytial virus (RSV), enteroviruses and coronaviruses. Methods to treat such infections are usually limited to treating symptoms and not the infectious agent.

 RSV is a virus classified in the genus Pneumovirus of the Paramyxovirus family. This virus can cause lower respiratory tract infections such as bronchiolitis
15 or pneumonia in, e.g., infants, young children, elderly persons or immunosuppressed patients. RSV can progress to cause serious or fatal symptoms in some cases (see e.g., Englund et al., *Ann. Int. Med.* 1988 1:203). Ribavirin aerosol has been used to treat RSV infections, but its toxicity limits its systemic use (see e.g., Gladu et al., *J. Toxic Env. Health* 1989 28:1). A vaccine of
20 inactivated RSV has been developed, but significant side effects are associated with it and additional therapies are needed.

 Otitis media, middle ear inflammation, is another common early childhood infection. Agents responsible for otitis media typically are respiratory syncytial viruses, rhinoviruses, influenza A viruses or adenoviruses (Henderson et al., *New*
25 *Eng. J. Med.* 1982 1377; Ruuskanen et al., *Pedr. Infect. Dis. J.* 1989 94). Prevention of respiratory virus infections decreases the incidence of otitis media (Heikkinen et al., *AJDC* 1991 445). Agents that treat or prevent such infections are needed.

 Influenza viruses are members of the Orthomyxovirus family. Seasonal
30 outbreaks occur almost yearly and occasional worldwide pandemics also arise. Treatment with vaccines are usually effective at preventing the disease, but the vaccine is needed each year, due to the variation of the flu viruses that arise each year. Amantadine has been used for treatment of ongoing infection, but it has some CNS toxicity. Influenza virus infection can progress to a primary influenza

viral pneumonia, which can not be treated with amantadine or rimantidine.

Additional agents to treat or prevent such infections are needed.

Herpesviruses such as herpes simplex viruses and related viruses (e.g., HSV-1, HSV-2, EBV, CMV, HHV-6, HHV-8) are members of the Herpesviridae family. Transmission of the viruses can arise from direct contact, e.g., HSV-1 through the oral cavity and HSV-2 through the genital tract. A number of therapeutic agents are available, e.g., acyclovir, trifluridine and vidarabine. These agents are not uniformly effective to treat the spectrum of infections that are associated with these viruses and additional agents to treat these infections are needed.

Retroviruses are associated with a number of infections, notably AIDS, and some cancers. The human immunodeficiency virus, HIV, (HIV-1, HIV-2, HTLV-III, LAV) is believed to be responsible for causing immune deficiency conditions in humans. Related viruses can lead to similar conditions in animals, e.g., SIV or SHIV in primates or FIV in cats. Loss of cell-mediated immunity and development of eventually fatal opportunistic infections frequently occurs in HIV infections. Most available treatment options have one or more limitations, such as toxicities or unwanted side effects and complicated dosing regimens. Large-scale efforts to identify additional treatment options for retrovirus infections are underway.

Hepatitis viruses such as human hepatitis A virus ("HAV"), human hepatitis B virus ("HBV"), and human hepatitis C virus ("HCV"), can lead to significant symptoms and mortality. For example, HCV infection is common, with estimates of worldwide prevalence of chronic hepatitis ranging from 90 million up to over 200 million. There is no vaccine or candidate vaccine for pre-exposure prophylaxis and no effective globulin for post-exposure prophylaxis. Related viruses of the Togaviridae, Hepadnaviridae, Flaviviridae and Picornaviridae families, including alphaviruses (also known as arboviruses, group A), flaviviruses (also known as arboviruses, group B)(such as yellow fever, as well as hepatitis C and hepatitis G), Rubiviruses (also known as rubella viruses)(such as rubella) and pestiviruses (also known as mucosal disease viruses, such as bovine virus diarrhea virus (BVDV)) are also significant causes of disease and mortality. Therapies for some of these infections exist, e.g., interferon treatment for HCV infection, but the treatments are not always effective and can have serious unwanted side effects. Considerable efforts are underway to identify additional therapeutic agents to use in treating

these infections.

The protozoan parasite *Toxoplasma gondii* is the etiologic agent of toxoplasmosis. The organism is a sporozoan that lives as an intracellular parasite in macrophages. It has evolved mechanisms to avoid killing by host cell defenses such as oxygen radicals and lysosomal enzymes. The parasite synthesizes molecules that appear to prevent lysosomes in infected macrophages from fusing with phagosomes that contain the parasite.



A number of flavonoids, coumarins and related compounds, methods to obtain them and their uses have been described. See, e.g., J.A. Manthey and B.S. Buslig, editors, *Flavonoids in the living system, Advances in experimental medicine and biology*, volume 439, Plenum Press, New York, 1998, chapter 15 (pages 191-225), chapter 16 (pages 227-235) and chapter 17 (pages 237-247), C.N. Alves et al., *Theochem.* 1999 491:123-131, J-H. Lee et al., *Saengyak Hakhoechi* 1999, 30:34-39, S.J. Semple et al., *J. Ethnopharmacology* 1999 68:283-288, E.Z. Baum et al., *Biochemistry* 1996 35:5847-5855, J.W. Critchfield et al., *AIDS Res. Hum. Retroviruses* 1996 12:39-46, H.K. Wang et al., *J. Med. Chem.* 1996 39:1975-1980, T. Nagai et al., *Antiviral Res.* 1995 26:11-25, T. Nagai et al., *Biol. Pharm. Bull.* 1995 18:295-299, N. Mahmood et al., *Antiviral Res.* 1993 22:189-99, J.A. Beutler et al., *J. Nat. Prod.* 1992 55:207-213, R.I. Brinkworth et al., *Biochem. Biophys. Res. Commun.* 1992 188:631-637, M.S. Chapman et al., *J. Mol. Biol.* 1991 217:455-463, I.T. Kusumoto et al., *Shoyakugaku Zasshi* 1991 45:240-54, T. Konoshima et al., *Shoyakugaku Zasshi* 1989 42:135-141, R. Vrijssen et al., *Antiviral Res.* 1987 7:35-42, J.L. Castrillo et al., *Virology* 1986 152:219-227, T. Horie et al., *J. Med. Chem.* 1986 29:2256-2262, T.N. Kaul et al., *J. Med. Virol.* 1985 15:71-79, T. Yoshinori et al., *Chem. Pharm. Bull.* 1985 33:3881-3886, P.G. Higgins et al., *British. Soc. Antimicrobial Chemother* 1984 403-409, Y. Graziani et al., *Eur. J. Biochem.* 1983 135:583-589 and U.S. patents 6063809, 5955256, 5877208, 5869701, 5830894, 5510375, 5489585 and 4238483.

The present invention provides compounds for use in these infectious conditions to treat or prevent them, or to ameliorate one or more symptoms associated with such infections. Also provided are compounds and compositions suitable for use in the methods.

SUMMARY OF THE INVENTION

In accordance with the present invention, a method is provided to treat or prevent a virus or a parasite infection comprising administering to a subject having the virus or parasite infection an effective amount of a compound having the

5 formula 1 or 2




10 wherein a double or a single bond is present at the dotted line and, when a double bond is present, (i) the optionally substituted phenyl ring at the 2- or 3-position is present and the R₈ that is bonded to that position is absent, and (ii) one R₈ at the adjacent 2- or 3-position is absent;

15 X₁ is -O- or -C(R₈)₂-;

X₂ is -C(O)- or -C(R₁₁)₂-;

each R₈ independently is -H, -OH, -SH, halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, glucuronide, a moiety that can hydrolyze to hydroxyl, a protecting group, a C₁₋₂₅ fatty acid, the residue of a formula 1 or 2 compound where a hydrogen atom is
20 removed to form the formula 1 or 2 compound radical, -CH₂CH=C(CH₃)₂, glucoside, a group having structure (B) or (C),



or, either R^8 and R^{10} at the 7 and 8 positions or both R^8 at the 5 and 6 positions together comprise a 6-membered aromatic ring and the remaining R^8 are independently selected from the substituents defined above,

or two R^8 bonded to the same carbon atom are oxygen ($=O$) or sulfur ($=S$);

R_{10} is hydroxyl ($-OH$), thiol ($-SH$), C_{1-6} alkyl, C_{1-6} alkoxy, a protecting group, a moiety that can hydrolyze to hydroxyl or thiol, neohesperidoside, apioglucoside, rutinoid, glucoside, galactoside, rhamnoside, arabinoside, or a stereoisomer, hydrate, analog, derivative or metabolite of any of these moieties, any of which are optionally independently substituted at one or more hydrogen atoms with $-OH$, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, glucuronide or a C_{1-25} fatty acid or R_{10} is $-H$, $-OH$ or halogen;

each R_{11} independently is $-H$, $-OH$, $-SH$, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, phenyl, glucuronide, a C_{1-25} fatty acid, or both R_{11} together are $=O$ or $=S$; and

the salts, stereoisomers, positional isomers, metabolites, tautomers, ionized forms and solvates thereof.

In some embodiments, the infection is a viral infection such as a picornavirus, a human immunodeficiency virus ("HIV") or human hepatitis C virus ("HCV") virus infection. In other embodiments, the infection is a parasite infection such as toxoplasmosis or malaria.

DETAILED DESCRIPTION OF THE INVENTION

As used herein and unless otherwise stated or implied by context, the following terms have the meanings defined here.

A "patient" or "subject" means a human or animal. Usually the animal is a vertebrate such as a primate, rodent, domestic animal or game animal. Primates include chimpanzees, cynomolgous monkeys, spider monkeys, and macaques, e.g., *Rhesus*. Rodents include mice, rats, woodchucks, ferrets, rabbits and hamsters. Domestic and game animals include cows, horses, pigs, deer, bison, buffalo, feline species, e.g., domestic cat, canine species, e.g., dog, fox, wolf, avian

species, e.g., chicken, emu, ostrich, and fish, e.g., trout, catfish and salmon.

Patient or subject includes any subset of the foregoing, e.g., all of the above, but excluding one or more groups or species such as humans, primates or rodents.

- "Alkyl" as used herein, unless stated to the contrary, is a saturated or
- 5 unsaturated C₁-C₁₈ hydrocarbon containing 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18 carbon atoms in the form of normal, secondary, tertiary, cyclic or mixed structures. Examples are -CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂CH₂CH₂CH₃, -CH₂CH(CH₃)₂, -CH(CH₃)CH₂CH₃, -C(CH₃)₃, -CH₂CH₂CH₂CH₂CH₃, -CH(CH₃)CH₂CH₂CH₃, -CH(CH₂CH₃)₂, -
 - 10 C(CH₃)₂CH₂CH₃, -CH(CH₃)CH(CH₃)₂, -CH₂CH₂CH(CH₃)₂, -CH₂CH(CH₃)CH₂CH₃, -CH₂C(CH₃)₃, -CH₂CH₂CH₂CH₂CH₂CH₃, -CH(CH₃)CH₂CH₂CH₂CH₃, -CH(CH₂CH₃)(CH₂CH₂CH₃), -C(CH₃)₂CH₂CH₂CH₃, -CH(CH₃)CH(CH₃)CH₂CH₃, -CH(CH₃)CH₂CH(CH₃)₂, -C(CH₃)(CH₂CH₃)₂, -CH(CH₂CH₃)CH(CH₃)₂, -C(CH₃)₂CH(CH₃)₂, -
 - 15 CH(CH₃)C(CH₃)₃, cyclopropyl, cyclobutyl, cyclopropylmethyl, cyclopentyl, cyclobutylmethyl, 1-cyclopropyl-1-ethyl, 2-cyclopropyl-1-ethyl, cyclohexyl, cyclopentylmethyl, 1-cyclobutyl-1-ethyl, 2-cyclobutyl-1-ethyl, 1-cyclopropyl-1-propyl, 2-cyclopropyl-1-propyl, 3-cyclopropyl-1-propyl, 2-cyclopropyl-2-propyl, 1-cyclopropyl-2-propyl, -CH=CH₂, -CH=CHCH₃, -CH₂CH=CH₂, -C(=CH₂)(CH₃), -
 - 20 CH=CHCH₂CH₃, -CH₂CH=CHCH₃, -CH₂CH₂CH=CH₂, -CH=C(CH₃)₂, -CH₂C(=CH₂)(CH₃), -C(=CH₂)CH₂CH₃, -C(CH₃)=CHCH₃, -CH(CH₃)CH=CH₂, -C=CHCH₂CH₂CH₃, -CHCH=CHCH₂CH₃, -CHCH₂CH=CHCH₃, -CHCH₂CH₂CH=CH₂, -C(=CH₂)CH₂CH₂CH₃, -C(CH₃)=CH₂CH₂CH₃, -CH(CH₃)CH=CHCH₃, -CH(CH₃)CH₂CH=CH₂, -CH₂CH=C(CH₃)₂, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, -CCH, -CCCH₃, -CH₂CCH, -CCCH₂CH₃, -CH₂CCCH₃, -CH₂CH₂CCH, -CH(CH₃)CCH, -CCCH₂CH₂CH₃, -CH₂CCCH₂CH₃, -CH₂CH₂CCCH₃ and -CH₂CH₂CH₂CCH.

- "Halogen" or "halo" means fluorine (-F), chlorine (-Cl), bromine (-Br) or
- 30 iodine (-I) and if more than one halogen is referred to (e.g., two or more variable groups may be a halogen), each halogen is independently selected.

"PEG" means an ethylene glycol polymer that contains about 20 to about 2000000 linked monomers, typically about 50-1000 linked monomers, usually about 100-300. Polyethylene glycols include PEGs containing various numbers of linked monomers, e.g., PEG20, PEG30, PEG40, PEG60, PEG80, PEG100,
5 PEG115, PEG 200, PEG 300, PEG400, PEG500, PEG600, PEG1000, PEG1500, PEG2000, PEG3350, PEG4000, PEG4600, PEG5000, PEG6000, PEG8000, PEG11000, PEG12000, PEG2000000 and any mixtures thereof.

Terms such as "excipient", "carrier", "pharmaceutically acceptable carrier" or the like are used interchangeably herein and they all mean a component or an
10 ingredient that is acceptable in the sense of being compatible with the other ingredients of compositions or formulations as disclosed herein and not overly deleterious to the patient or animal to which the formulation is to be administered. As used here, excipients and carriers include solids and liquids. Typical excipients include cellulose, methylcellulose, starch, microcrystalline cellulose, lactose,
15 sucrose, glucose, magnesium stearate, a C₂₋₁₂ alcohol (e.g., ethanol), glycerol, peanut oil, a PEG, propylene glycol or a vegetable oil such as safflower oil, sesame oil or soybean oil. Such components are typically used in the pharmaceutical or veterinary formulation arts, e.g., fillers, binders, disintegrants and lubricants.

Unless otherwise specified, expressions that refer to "a formula 1 or 2
20 compound(s)", and the like mean compositions or methods, e.g., methods to treat a viral or parasite infection as disclosed herein, where one or more than one formula 1 or formula 2 compound is present, typically 1, 2, 3 or 4. The formula 1 and 2 compounds are sometimes collectively referred herein to as the "compounds of the invention", or "compounds of the present invention" or the like.


25 Terms such as a "moiety that can convert to hydroxyl or thiol *in vivo*", "a derivative that can convert to a formula 1 or 2 compound" and similar terms means an organic moiety that can convert chemically or enzymatically to a hydroxyl or thiol group or to the formula 1 or 2 compound *in vitro* or *in vivo*. Typically these moieties comprise an ester structure (-C(O)-O-) that links the formula 1 or 2
30 compound to the organic moiety and the conversion is chemical or enzymatic hydrolysis, e.g., hydrolysis is mediated by low pH in the gut or esterase activity in cells (e.g., virus infected cells), tissues, blood or plasma.

"Ester" or "ester structure" means a moiety that comprises a -C(O)-O- structure. Typically, esters as used here comprise an organic moiety containing

about 1-50 carbon atoms (e.g., about 2-12 carbon atoms) and 0 to about 10 independently selected heteroatoms (e.g., O, S, N, P, Si), where the organic moiety is bonded to a formula 1 steroid nucleus at R² through the -C(O)-O- structure, e.g., organic moiety-C(O)-O-steroid or organic moiety-O-C(O)-steroid.

- 5 The organic moiety usually comprises one or more of any of the organic groups described above, e.g., C₁₋₂₀ alkyl moieties, C₂₋₂₀ alkenyl moieties, C₂₋₂₀ alkynyl moieties, aryl moieties, C₂₋₉ heterocycles or substituted derivatives of any of these, e.g., comprising 1, 2, 3, 4 or more substituents, where each substituent is independently chosen. Typical substitutions for hydrogen or carbon atoms in these
- 10 organic groups include 1, 2, 3, 4 or more, usually 1, 2, or 3 -O-, -S-, -NR^{PR}- (including -NH-), -C(O)-, =O, =S, -N(R^{PR})₂ (including -NH₂), -C(O)OR^{PR} (including -C(O)OH), -OC(O)R^{PR} (including -O-C(O)-H), -OR^{PR} (including -OH), -SR^{PR} (including -SH), -NO₂, -CN, -NHC(O)-, -C(O)NH-, -OC(O)-, -C(O)O-, -O-A8, -S-A8, -C(O)-A8, -OC(O)-A8, -C(O)O-A8, =N-, -N=, =N-OH, -OPO₃(R^{PR})₂, -OSO₃H₂ or
- 15 halogen moieties or atoms, where each R^{PR} is -H, an independently selected protecting group or both R^{PR} together comprise a protecting group, and A8 is C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ alkyl-aryl (e.g., benzyl), aryl (e.g. phenyl) or C₀₋₄ alkyl-C₂₋₉ heterocycle. Substitutions are independently chosen. The organic moiety includes compounds defined by the R₄ variable. The organic moieties
- 20 exclude obviously unstable moieties, e.g., -O-O-, except where such unstable moieties are transient species that one can use to make a compound with sufficient chemical stability for the one or more of the uses described herein. The substitutions listed above are typically substituents that one can use to replace one or more carbon atoms, e.g., -O- or -C(O)-, or one or more hydrogen atom, e.g.,
- 25 halogen, -NH₂ or -OH.

As used herein, the neohesperidoside, rutinoside and glucoside groups have the structures



wherein one or more of the hydrogen atoms are optionally independently substituted with hydroxy, halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, glucuronide, a C₁₋₁₀ ester, or a C₁₋₂₅ fatty acid, e.g., acetate, acetyl or butyrate.

- 5 Heterocycle. "Heterocycle" or "heterocyclic" includes by way of example and not limitation these heterocycles described in Paquette, Leo A.; "Principles of Modern Heterocyclic Chemistry" (W. A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; "The Chemistry of Heterocyclic Compounds, A series of Monographs" (John Wiley & Sons, New York, 1950 to present), in particular
- 10 Volumes 13, 14, 16, 19, and 28; and *J. Am. Chem. Soc.* 1960, 82:5566; and U.S. patent 5763483, all of which are incorporated herein by reference.

- Examples of heterocycles include by way of example and not limitation
- pyridyl, thiazolyl, tetrahydrothiophenyl, sulfur oxidized tetrahydrothiophenyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl,
- 15 thianaphthalenyl, indolyl, indolenyl, quinoliny, isoquinoliny, benzimidazolyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl, tetrahydrofuranyl, tetrahydroquinoliny, tetrahydroisoquinoliny, decahydroquinoliny, octahydroisoquinoliny, azociny, triazinyl, 6H-1,2,5-thiadiaziny, 2H,6H-1,5,2-dithiaziny, thienyl, thianthrenyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl,
- 20 phenoxathiiny, 2H-pyrroly, isothiazolyl, isoxazolyl, pyraziny, pyridaziny, indoliziny, isoindolyl, 3H-indolyl, 1H-indazolyl, puriny, 4H-quinoliziny, phthalaziny, naphthyridiny, quinoxaliny, quinazoliny, cinnoliny, pteridiny, 4aH-carbazolyl, carbazolyl, β -carboliny, phenanthridiny, acridiny, pyrimidinyl, phenanthroliny, phenaziny, phenothiaziny, furazany, phenoxaziny, isochromany, chromany,
- 25 imidazolidiny, imidazoliny, pyrazolidiny, pyrazoliny, piperaziny, indoliny,

isoindolynyl, quinuclidinyl, morpholynyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolynyl, and isatinoyl.

By way of example and not limitation, carbon bonded heterocycles are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline. Still more typically, carbon bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or 5-thiazolyl.

By way of example and not limitation, nitrogen bonded heterocycles are bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, 1H-indazole, position 2 of a isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or β -carboline. Typically, nitrogen bonded heterocycles include 1-aziridyl, 1-azetidyl, 1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl, and 1-piperidyl.

"Heteroaryl" means an aromatic ring or two or more fused rings that contain one or more aromatic rings where the ring or fused rings comprise 1, 2, 3 or more heteroatoms, usually oxygen (-O-), nitrogen (-NX-) or sulfur (-S-) where X is -H, a protecting group or C₁₋₆ alkyl, usually -H. Examples are as described for heterocycle.

Protecting groups. Various groups that the formula 1, 1 or 2 compounds may comprise include, e.g., substituted alkyl groups, substituted alkenyl groups, esters or substituted heterocycles, which can contain one or more reactive moieties such as hydroxyl, or thiol. Intermediates used to make formula 1 or formula 1 or 2 compounds may be protected as is apparent in the art. Noncyclic and cyclic protecting groups and corresponding cleavage reactions are described in "Protective Groups in Organic Chemistry", Theodora W. Greene (John Wiley & Sons, Inc., New York, 1991, ISBN 0-471-62301-6) (hereafter "Greene"). In the

context of the present invention, these protecting groups are groups that can be removed from the molecule of the invention without irreversibly changing the covalent bond structure or oxidation/reduction state of the remainder of the molecule. For example, the protecting group, -X, that is bonded to a -OX or -NHX group can be removed to form -OH or -NH₂, respectively, without affecting other covalent bonds in the molecule. At times, when desired, more than one protecting group can be removed at a time, or they can be removed sequentially. In compounds of the invention containing more than one protecting group, the protecting groups are the same or different.

Protecting groups are intended to be removed by known procedures, although it will be understood that the protected intermediates fall within the scope of this invention. The removal of the protecting group may be arduous or straightforward, depending upon the economics and nature of the conversions involved. In general, one will use a protecting group with exocyclic amines or with carboxyl groups during synthesis of a formula 1 compound. For most therapeutic applications amine groups should be deprotected. Protecting groups commonly are employed to protect against covalent modification of a sensitive group in reactions such as alkylation or acylation. Ordinarily, protecting groups are removed by, e.g. hydrolysis, elimination or aminolysis. Thus, simple functional considerations will suffice to guide the selection of a reversible or an irreversible protecting group at a given locus on the invention compounds. Suitable protecting groups and criteria for their selection are described in T.W. Greene and P.G.M. Wuts, Eds. "Protective Groups in Organic Synthesis" 2nd edition, Wiley Press, at pp. 10-142, 143-174, 175-223, 224-276, 277-308, 309-405 and 406-454, which is incorporated herein by reference.

Determination of whether a group is a protecting group is made in the conventional manner, e.g., as illustrated by Kocienski, Philip J.; "*Protecting Groups*" (Georg Thieme Verlag Stuttgart, New York, 1994) (hereafter "Kocienski"), Section 1.1, page 2, and Greene Chapter 1, pages 1-9; and U.S. patent 5,763,483, all of which are incorporated herein by reference. In particular, a group is a protecting group if when, based on mole ratio, 90% of that protecting group has been removed by a deprotection reaction, no more than 50%, preferably 25%, more preferably 10%, of the deprotected product molecules of the invention have undergone changes to their covalent bond structure or oxidation/reduction state

other than those occasioned by the removal of the protecting group. When multiple protecting groups of the same type are present in the molecule, the mole ratios are determined when all of the groups of that type are removed. When multiple protecting groups of different types are present in the molecule, each type of protecting group is treated (and the mole ratios are determined) independently or together with others depending on whether the deprotection reaction conditions pertinent to one type are also pertinent to the other types present. In one embodiment of the invention, a group is a protecting group if when, based on mole ratio determined by conventional techniques, 90% of that protecting group has been removed by a conventional deprotection reaction, no more than 50%, preferably 25%, more preferably 10%, of the deprotected product molecules of the invention have undergone irreversible changes to their covalent bond structure or oxidation/reduction state other than those occasioned by the removal of the protecting group. Irreversible changes require chemical reactions (beyond those resulting from aqueous hydrolysis, acid/base neutralization or conventional separation, isolation or purification) to restore the covalent bond structure or oxidation/reduction state of the deprotected molecule of the invention.

Protecting groups are also described in detail together with general concepts and specific strategies for their use in Kocienski, Philip J.; "Protecting Groups" (Georg Thieme Verlag Stuttgart, New York, 1994), which is incorporated by reference in its entirety herein. In particular Chapter 1, Protecting Groups: An Overview, pages 1-20, Chapter 2, Hydroxyl Protecting Groups, pages 21-94, Chapter 3, Diol Protecting Groups, pages 95-117, Chapter 4, Carboxyl Protecting Groups, pages 118-154, Chapter 5, Carbonyl Protecting Groups, pages 155-184, Chapter 6, Amino Protecting Groups, pages 185-243, Chapter 7, Epilog, pages 244-252, and Index, pages 253-260, are incorporated with specificity in the context of their contents. More particularly, Sections 2.3 Silyl Ethers, 2.4 Alkyl Ethers, 2.5 Alkoxyalkyl Ethers (Acetals), 2.6 Reviews (hydroxy and thiol protecting groups), 3.2 Acetals, 3.3 Silylene Derivatives, 3.4 1,1,3,3-Tetraisopropylidisiloxanylidene Derivatives, 3.5 Reviews (diol protecting groups), 4.2 Esters, 4.3 2,6,7-Trioxabicyclo[2.2.2]octanes [OBO] and Other Ortho Esters, 4.4 Oxazolines, 4.5 Reviews (carboxyl protecting groups), 5.2 O,O-Acetals, 5.3 S,S-Acetals, 5.4 O,S-Acetals, 5.5 Reviews (carbonyl protecting groups), 6.2 N-Acyl Derivatives, 6.3 N-Sulfonyl Derivatives, 6.4 N-Sulfenyl Derivatives, 6.5 N-Alkyl Derivatives, 6.6 N-Silyl

Derivatives, 6.7 Imine Derivatives, and 6.8 Reviews (amino protecting groups), are each incorporated with specificity where protection/deprotection of the requisite functionalities is discussed. Further still, the tables "Index to the Principal Protecting Groups" appearing on the inside front cover and facing page,

- 5 "Abbreviations" at page xiv, and "Reagents and Solvents" at page xv are each incorporated in their entirety herein.

Typical hydroxy protecting groups are described in Greene at pages 14-118 and include Ethers (Methyl); Substituted Methyl Ethers (Methoxymethyl, Methylthiomethyl, t-Butylthiomethyl, (Phenyldimethylsilyl)methoxymethyl, 10 Benzyloxymethyl, p-Methoxybenzyloxymethyl, (4-Methoxyphenoxy)methyl, Guaiacolmethyl, t-Butoxymethyl, 4-Pentenylloxymethyl, Siloxymethyl, 2-Methoxyethoxymethyl, 2,2,2-Trichloroethoxymethyl, Bis(2-chloroethoxy)methyl, 2-(Trimethylsilyl)ethoxymethyl, Tetrahydropyranyl, 3-Bromotetrahydropyranyl, Tetrahydrothiopyranyl, 1-Methoxycyclohexyl, 4-methoxytetrahydropyranyl, 4- 15 Methoxytetrahydrothiopyranyl, 4-Methoxytetrahydrothiopyranyl S,S-Dioxido, 1-[(2-Chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl, 1,4-Dioxan-2-yl, Tetrahydrofuranyl, Tetrahydrothiofuranyl, 2,3,3a,4,5,6,7,7a-Octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl); Substituted Ethyl Ethers (1-Ethoxyethyl, 1-(2-Chloroethoxy)ethyl, 1-Methyl-1-methoxyethyl, 1-Methyl-1-benzyloxyethyl, 1- 20 Methyl-1-benzyloxy-2-fluoroethyl, 2,2,2-Trichloroethyl, 2-Trimethylsilylethyl, 2-(Phenylselenyl)ethyl, t-Butyl, Allyl, p-Chlorophenyl, p-Methoxyphenyl, 2,4-Dinitrophenyl, Benzyl); Substituted Benzyl Ethers (p-Methoxybenzyl, 3,4-Dimethoxybenzyl, o-Nitrobenzyl, p-Nitrobenzyl, p-Halobenzyl, 2,6-Dichlorobenzyl, p-Cyanobenzyl, p-Phenylbenzyl, 2- and 4-Picolyl, 3-Methyl-2-picolyl N-Oxido, 25 Diphenylmethyl, p, p'-Dinitrobenzhydryl, 5-Dibenzosuberyl, Triphenylmethyl, alpha-Naphthylidiphenylmethyl, p-methoxyphenyldiphenylmethyl, Di(p-methoxyphenyl)phenylmethyl, Tri(p-methoxyphenyl)methyl, 4-(4'-Bromophenacyloxy)phenyldiphenylmethyl, 4,4', 4''-Tris(4,5-dichlorophthalimidophenyl)methyl, 4,4', 4''-Tris(levulinoyloxyphenyl)methyl, 4,4', 4''- 30 Tris(benzoyloxyphenyl)methyl, 3-(Imidazol-1-ylmethyl)bis(4', 4''-dimethoxyphenyl)methyl, 1,1-Bis(4-methoxyphenyl)-1'-pyrenylmethyl, 9-Anthryl, 9-(9-Phenyl)xanthylenyl, 9-(9-Phenyl-10-oxo)anthryl, 1,3-Benzodithiolan-2-yl, Benzisothiazolyl, S,S-Dioxido); Silyl Ethers (Trimethylsilyl, Triethylsilyl, Triisopropylsilyl, Dimethylisopropylsilyl, Diethylisopropylsilyl, Dimethylthexylsilyl, t-

Butyldimethylsilyl, t-Butyldiphenylsilyl, Tribenzylsilyl, Tri-p-xylylsilyl, Triphenylsilyl, Diphenylmethylsilyl, t-Butylmethoxyphenylsilyl); Esters (Formate, Benzoylformate, Acetate, Chloroacetate, Dichloroacetate, Trichloroacetate, Trifluoroacetate, Methoxyacetate, Triphenylmethoxyacetate, Phenoxyacetate, p-
5 Chlorophenoxyacetate, p-poly-Phenylacetate, 3-Phenylpropionate, 4-Oxopentanoate (Levulinate), 4,4-(Ethylenedithio)pentanoate, Pivaloate, Adamantoate, Crotonate, 4-Methoxycrotonate, Benzoate, p-Phenylbenzoate, 2,4,6-Trimethylbenzoate (Mesitoate); Carbonates (Methyl, 9-Fluorenylmethyl, Ethyl, 2,2,2-Trichloroethyl, 2-(Trimethylsilyl)ethyl, 2-(Phenylsulfonyl)ethyl, 2-
10 (Triphenylphosphonio)ethyl, Isobutyl, Vinyl, Allyl, p-Nitrophenyl, Benzyl, p-Methoxybenzyl, 3,4-Dimethoxybenzyl, o-Nitrobenzyl, p-Nitrobenzyl, S-Benzyl Thiocarbonate, 4-Ethoxy-1-naphthyl, Methyl Dithiocarbonate); Groups With Assisted Cleavage (2-Iodobenzoate, 4-Azidobutyrate, 4-Nitro-4-methylpentanoate, o-(Dibromomethyl)benzoate, 2-Formylbenzenesulfonate, 2-
15 (Methylthiomethoxy)ethyl Carbonate, 4-(Methylthiomethoxy)butyrate, 2-(Methylthiomethoxymethyl)benzoate); Miscellaneous Esters (2,6-Dichloro-4-methylphenoxyacetate, 2,6-Dichloro-4-(1,1,3,3-tetramethylbutyl)phenoxyacetate, 2,4-Bis(1,1-dimethylpropyl)phenoxyacetate, Chorodiphenylacetate, Isobutyrate, Monosuccinoate, (E)-2-Methyl-2-butenate (Tigloate), o-
20 (Methoxycarbonyl)benzoate, p-poly-Benzoate, α -Naphthoate, Nitrate, Alkyl N,N,N', N'-Tetramethylphosphorodiamidate, N-Phenylcarbamate, Borate, Dimethylphosphinothioyl, 2,4-Dinitrophenylsulfenate); and Sulfonates (Sulfate, Methanesulfonate (Mesylate), Benzylsulfonate, Tosylate).

More typically hydroxy protecting groups include substituted methyl ethers,
25 substituted benzyl ethers, silyl ethers, and esters including sulfonic acid esters, still more typically, trialkylsilyl ethers, tosylates and acetates.

Typical 1,2- and 1,3-diol protecting groups are described in Greene at pages 118-142 and include Cyclic Acetals and Ketals (Methylene, Ethylidene, 1-t-Butylethylidene, 1-Phenylethylidene, (4-Methoxyphenyl)ethylidene, 2,2,2-
30 Trichloroethylidene, Acetonide (Isopropylidene), Cyclopentylidene, Cyclohexylidene, Cycloheptylidene, Benzylidene, p-Methoxybenzylidene, 2,4-Dimethoxybenzylidene, 3,4-Dimethoxybenzylidene, 2-Nitrobenzylidene); Cyclic Ortho Esters (Methoxymethylene, Ethoxymethylene, Dimethoxymethylene, 1-Methoxyethylidene, 1-Ethoxyethylidene, 1,2-Dimethoxyethylidene, alpha-

Methoxybenzylidene, 1-(N,N-Dimethylamino)ethylidene Derivative, alpha-(N,N-Dimethylamino)benzylidene Derivative, 2-Oxacyclopentylidene); and Silyl Derivatives (Di-t-butylsilylene Group, 1,3-(1,1,3,3-Tetraisopropylidisiloxanylidene) Derivative, Tetra-t-butoxydisiloxane-1,3-diylidene Derivative, Cyclic Carbonates, Cyclic Boronates, Ethyl Boronate, Phenyl Boronate).

More typically, 1,2- and 1,3-diol protecting groups include epoxides and acetonides.

Stereoisomers. The formula 1 or 2 compounds include enriched or resolved optical isomers at any or all asymmetric atoms as are apparent from the depictions.

Both racemic and diastereomeric mixtures, as well as the individual optical isomers can be isolated or synthesized so as to be substantially free of their enantiomeric or diastereomeric partners, and these are all within the scope of the invention.

Chiral centers may be found in invention compounds at, for example, R⁸, or R¹⁰.

One or more of the following methods are used to prepare the enantiomerically enriched or pure isomers herein. The methods are listed in approximately their order of preference, i.e.; one ordinarily should employ stereospecific synthesis from chiral precursors before chromatographic resolution before spontaneous crystallization.

Stereospecific synthesis is described in the examples. Methods of this type conveniently are used when the appropriate chiral starting material is available and reaction steps are chosen that do not result in undesired racemization at chiral sites. One advantage of stereospecific synthesis is that it does not produce undesired enantiomers that must be removed from the final product, thereby lowering overall synthetic yield. In general, those skilled in the art would understand what starting materials and reaction conditions should be used to obtain the desired enantiomerically enriched or pure isomers by stereospecific synthesis.

If a suitable stereospecific synthesis cannot be empirically designed or determined with routine experimentation then those skilled in the art would turn to other methods. One method of general utility is chromatographic resolution of enantiomers on chiral chromatography resins. These resins are packed in columns, commonly called Pirkle columns, and are commercially available. The columns contain a chiral stationary phase. The racemate is placed in solution and loaded onto the column, and thereafter separated by HPLC. See for example,

Proceedings Chromatographic Society - International Symposium on Chiral Separations, Sept. 3-4, 1987, which is incorporated herein by reference. Examples of chiral columns that could be used to screen for the optimal separation technique would include Diacel Chriacel OD, Regis Pirkle Covalent D-phenylglycine, Regis Pirkle Type 1A, Astec Cyclobond II, Astec Cyclobond III, Serva Chiral D-DL=Daltosil 100, Bakerbond DNBLau, Sumipax OA-1000, Merck Cellulose Triacetate column, Astec Cyclobond I-Beta, or Regis Pirkle Covalent D-Naphthylalanine. Not all of these columns are likely to be effective with every racemic mixture. However, those skilled in the art understand that a certain amount of routine screening may be required to identify the most effective stationary phase. When using such columns it is desirable to employ embodiments of the compounds of this invention in which the charges are not neutralized, e.g., where acidic functionalities such as carboxyl are not esterified or amidated.

Another method entails converting the enantiomers in the mixture to diastereomers with chiral auxiliaries and then separating the conjugates by ordinary column chromatography. This is a very suitable method, particularly when the embodiment contains a free hydroxyl that will form a salt or covalent bond to a chiral auxiliary. Chirally pure amino acids, organic acids or organosulfonic acids are all worthwhile exploring as chiral auxiliaries, all of which are well known in the art. Salts with such auxiliaries can be formed, or they can be covalently (but reversibly) bonded to the functional group.

Enzymatic resolution is another method of potential value. In such methods one prepares covalent derivatives of the enantiomers in the racemic mixture, generally lower alkyl esters, and then exposes the derivative to enzymatic cleavage, generally hydrolysis. For this method to be successful an enzyme must be chosen that is capable of stereospecific cleavage, so it is frequently necessary to routinely screen several enzymes. If esters are to be cleaved, then one selects a group of esterases, phosphatases, and lipases and determines their activity on the derivative. Typical esterases are from liver, pancreas or other animal organs, and include porcine liver esterase.

If the enantiomeric mixture separates from solution or a melt as a conglomerate, i.e., a mixture of enantiomerically pure crystals, then the crystals can be mechanically separated, thereby producing the enantiomerically enriched

preparation. This method, however, is not practical for large-scale preparations and is of limited value for true racemic compounds.

Asymmetric synthesis is another technique for achieving enantiomeric enrichment. For example, a chiral protecting group is reacted with the group to be protected and the reaction mixture allowed to equilibrate. If the reaction is enantiomerically specific then the product will be enriched in that enantiomer.

Further guidance in the separation of enantiomeric mixtures can be found, by way of example and not limitation, in "Enantiomers, Racemates, and resolutions", Jean Jacques, Andre Collet, and Samuel H. Wilen (Krieger Publishing Company, Malabar, FL, 1991, ISBN 0-89464-618-4): Part 2, Resolution of Enantiomer Mixture, pages 217-435; more particularly, section 4, Resolution by Direct Crystallization, pages 217-251, section 5, Formation and Separation of Diastereomers, pages 251-369, section 6, Crystallization-Induced Asymmetric Transformations, pages 369-378, and section 7, Experimental Aspects and Art of Resolutions, pages 378-435; still more particularly, section 5.1.4, Resolution of Alcohols, Transformation of Alcohols into Salt-Forming Derivatives, pages 263-266, section 5.2.3, Covalent Derivatives of Alcohols, Thiols, and Phenols, pages 332-335, section 5.1.1, Resolution of Acids, pages 257-259, section 5.1.2, Resolution of Bases, pages 259-260, section 5.1.3, Resolution of Amino Acids, page 261-263, section 5.2.1, Covalent Derivatives of Acids, page 329, section 5.2.2, Covalent derivatives of Amines, pages 330-331, section 5.2.4, Covalent Derivatives of Aldehydes, Ketones, and Sulfoxides, pages 335-339, and section 5.2.7, Chromatographic Behavior of Covalent Diastereomers, pages 348-354, all of which are incorporated herein by reference.


In some embodiments, the ester is an organic moiety comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms and 0, 1, 2, 3, 4, 5, 6, 7 or 8 independently selected O, S, N, P, or Si atoms, but, if a Si or P atom is present, only one Si or P is present, wherein the organic moiety is optionally selected from C₁₋₁₂ alkyl, C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, aryl, a C₂₋₉ heterocycle or a substituted derivative of any of these comprising 1, 2, 3, 4 or more substituents, wherein each substituent is independently chosen and is selected from -O-, -S-, -NR^{PR}- (including -NH-), -C(O)-, =O, =S, -N(R^{PR})₂ (including -NH₂), -C(O)OR^{PR} (including -C(O)OH), -OC(O)R^{PR} (including -O-C(O)-H), -OR^{PR} (including -OH), -SR^{PR} (including -SH), -NO₂, -CN, -NHC(O)-, -C(O)NH-, -OC(O)-, -C(O)O-, -O-A8, -S-A8, -C(O)-A8, -OC(O)-A8, -

$C(O)O-A8$, $=N-$, $-N=$, $=N-OH$, $-OPO_3(R^{PR})_2$, $-OSO_3H_2$ and halogen moieties or atoms, where each R^{PR} is $-H$, an independently selected protecting group or both R^{PR} together comprise a protecting group, and $A8$ is C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-4} alkyl-aryl (e.g., benzyl), aryl (e.g. phenyl) or C_{1-4} alkyl- C_{2-9} heterocycle.


5 G12 moieties include $-CH_3$, $-C_2H_5$, $-C_3H_7$, $-C_4H_9$, $-C_6H_{13}$, $-CH_2-C_6H_5$, $-C_2H_4-C_6H_5$, $-C_3H_6-C_6H_5$, $-C_6H_5$, $-CH_2$ -heterocycle, $-CH_2-CH_2$ -heterocycle and a heterocycle, and of which are substituted with one, two, three or more independently selected $-O-$, $-S-$, $-F$, $-Cl$, $-Br$, $-I$, $-NH-$, $=O$, $-CN$, $-OCH_3$, $-OC_2H_5$, $-OC_4H_9$, $-NO_2$, $-NH_2$, $-COOH$, or $-NH-C(O)-$ moieties.

10 An aspect of the invention comprises administering an effective amount of a compound of formula 1 or 2 compound preventing or treating one or more conditions described herein, e.g., *Trypanosome* or *Plasmodium* infections in a subject. Exemplary formula 1 or 2 compounds include bavachinin A, didymin (isosakuranetin-7-rutinoside or neoponcirin), flavanomarein (isookanine-7-


15 glucoside), flavanone azine, flavanone diacetylhydrazone, flavanone hydrazone, silybin, which has the structure




silychristin,




20 isosilybin,



silandrin,




compounds having the structure (E)





5

(E),


baicalein trimethyl ether (4'-hydroxy-5,6,7-trimethoxyflavone)



3',4'-dihydroxy- α -naphthoflavone,


3',4'-dihydroxy- β -naphthoflavone,

3',4'-dibenzyloxy-5,6,7-trimethoxyflavone,




5

3',4'-dihydroxy-5,6,7-trimethoxyflavone,




and 3',4'-diacetoxy-5,6,7-trimethoxyflavone




10



Also within the scope of the invention are compounds related to compounds of formula 1 or 2 wherein one of the bonds between atoms 1, 2, 3 and 4 is absent; that is the ring comprising atoms 1, 2, 3 and 4 is not closed, for example 2-(3,4-dibenzyloxy)-4,5,6-trimethoxyacetophenone

















and 3',4'-dibenzyloxy-2-hydroxy-4,5,6-trimethoxydibenzoylmethane



10 The formula 1 and 2 compounds encompass a number of natural and synthetic flavonoids, including certain flavones, flavans, and their iso analogs. Such compounds include compounds of formulas 50-65







wherein

10 R_8 at the 6-position independently are -H, -OH, -F, -Cl, -Br, -I, C_{1-6} alkyl, C_{1-6} alkoxy, glucuronide, a C_{1-25} fatty acid, glucoside, $-CH_2CH=C(CH_3)_2$ or a group having the structure (B);

15 R_8 at the 8-position independently are -H, -OH, -F, -Cl, -Br, -I, C_{1-6} alkyl, C_{1-6} alkoxy, glucuronide, a C_{1-25} fatty acid, glucoside, $-CH_2CH=C(CH_3)_2$ or the residue of a formula 50-65 compound where a hydrogen atom is removed to form the formula 50-65 radical;

R₈A independently are -H, -OH, -F, -Cl, -Br, -I, C₁₋₆ alkyl, C₁₋₆ alkoxy, glucuronide, a C₁₋₂₅ fatty acid, glucoside, -CH₂CH=C(CH₃)₂ or a group having the structure (C);

the remaining R₈ independently are -H, -OH, -F, -Cl, -Br, -I, C₁₋₆ alkyl, C₁₋₆ alkoxy, glucuronide, a C₁₋₂₅ fatty acid or -CH₂-CH=C(CH₃)₂; and

R₁₀ (i) is -OH or -F, -Cl, -Br, -I, C₁₋₆ alkyl, C₁₋₆ alkoxy, neohesperidoside, apioglucoside, rutinose, glucoside, galactoside, rhamnoside, arabinoside, or a stereoisomer, hydrate, analog, derivative or metabolite of any of these moieties, any of which are optionally independently substituted at one or more hydrogen atoms with -OH, -F, -Cl, -Br, -I, C₁₋₆ alkyl, C₁₋₆ alkoxy, glucuronide or a C₁₋₂₅ fatty acid, or (ii) R₁₀ is the radical of bavachinin A, didymin, flavanomarein, flavanone azine, flavanone diacetylhydrazone, flavanone hydrazone, silybin, silychistin, isosilybin, silandrin, a moiety of structure (E) or a stereoisomer or metabolite of any of these moieties.

Invention embodiments include the use of any of the compounds of formula 50-65 in the therapeutic applications in this disclosure, wherein 1, 2, 3, 4, 5 or 6 of the R₈, R₁₀ or R₁₁ moieties are independently selected from optionally substituted C₁₋₁₀ alkoxy, an optionally substituted C₁₋₁₀ ester or an optionally substituted saccharide or oligosaccharide, e.g., 1, 2, 3, 4, 5, 6 or 7, R₈, R₁₀ and R₁₁

independently are -OCH₃, -OC₂H₅, -OC₄H₉, -OC₆H₁₃, -OCOOH, -OCH₂COOH, -OCH₂CH₂CH₂COOH, -OC₅H₁₀COOH, -OCH₂CH₂OCH₃, -OCH₂CH₂SCH₃, -OC(O)CH₃, -OC(O)C₂H₅, -OC(O)C₄H₉, -OC(O)C₆H₁₃, -OC(O)CH₂CH₂OCH₃, -OC(O)CH₂CH₂SCH₃, -OC(O)-CH₂-C₆H₅, -OC(O)-CH₂-C₆H₄OCH₃, -OC(O)-CH₂-C₆H₄OH, -OC(O)-CH₂-C₆H₄OC(O)OH, -OH, -SH, =O, =S, phenyl, benzyl, glucoside, rhamnoside, riboside, 2'-deoxyriboside or arabinoside. Typically in these embodiments, none, one, two or three of the R₈, R₁₀ and/or R₁₁ moieties independently comprise -SH or =S.

Generally, the formula 1 or 2 compounds comprise 0, 1, 2 or 3 =O moieties, which includes any of the compounds of structure 50-65 and any of the embodiments described herein.

For embodiments where two variable moieties, e.g., two R₈ at the 2 or 3 position or two R₁₁ or at X₂, are bonded to the same carbon atom of a formula 1 or 2 compound, (1) one of the two variable groups may be hydrogen while the other is

hydrogen or one of the other defined substituents for that variable group or (2) both variable groups together are oxygen (=O) or sulfur (=S).

Methods of administration and formulations. Compounds of the family of compounds outlined herein have been found in to have valuable pharmaceutical properties as, e.g., anti-viral agents, in relation to the viruses, which were heretofore unknown.

Compounds used according to this invention are administered as treatments against infections by any suitable route including enteral, parenteral, topical, oral, rectal, nasal or vaginal routes. Parenteral routes include subcutaneous, intramuscular, intravenous and sublingual administration. Topical routes include buccal and sublingual administration. Additionally, compositions of the present invention may be implanted into a patient or injected using a drug delivery system. See, for example, Urquhart, et al., Ann. Rev. Pharmacol. Toxicol. 24: 199-236 (1984); Lewis, ed. "Controlled Release of Pesticides and Pharmaceuticals" (Plenum Press, New York, 1981); U.S. Pat. No. 3,773,919; and U.S. Pat. No. 3,270,960.

The present invention further provides use of any compound described herein in the manufacture or preparation of formulations, and especially pharmaceutical formulations, for use in treatments against specific infectious agents such as HIV or respiratory viruses. The invention also provides the pharmaceutical formulations themselves. Such formulations typically comprise one or more acceptable excipients and a formula 1 or 2 compound.

Pharmaceutical preparations prepared according to the invention include the compounds described herein contained in a gelatin capsule, in tablet form, dragee, syrup, suspension, topical cream, suppository, injectable solution, or kits for the preparation of syrups, suspension, topical cream, suppository or injectable solution just prior to use. Also, compounds described herein may be included in composites, which facilitate its slow release into the blood stream, e.g., silicon disc, polymer beads.

Pharmaceutical preparations prepared according to the invention include the employment of compounds described herein in admixture with conventional excipients, that is, pharmaceutically acceptable organic or inorganic carrier substances which do not deleteriously react with the compounds. Suitable pharmaceutically acceptable carriers include, but are not limited to water, salt

solutions, alcohols, gum arabic, vegetable oils, gelatin, carbohydrates, magnesium stearate, talc, silicic acid, viscous paraffin, fatty acid mono- and di-glycerides, etc.

The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy.

- 5 Techniques, excipients and formulations generally are found in, e.g., *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA 1985, 17th edition, Nema et al., *PDA J. Pharm. Sci. Tech.* 1997 51:166-171. Methods to make invention formulations include the step of bringing into association or contacting a formula 1 or 2 compound with one or more excipients or carriers. In general, the
10 formulations are prepared by uniformly and intimately bringing into association the formula 1 or 2 compound with liquid excipients or finely divided solid excipients or both, and then, if appropriate, shaping the product.

- The preparative procedure may include the sterilization of the pharmaceutical preparations. The compounds may be mixed with auxiliary agents
15 such as lubricants, preservatives, stabilizers, salts for influencing osmotic pressure, etc., which do not react deleteriously with the compounds.

- Examples of an injectable form include solutions, suspensions and emulsions. The compounds of the present invention can be injected in association with a pharmaceutical carrier such as normal saline, Ringer's solution, dextrose
20 solution and other aqueous carriers known in the art. Appropriate non-aqueous carriers may also be used and examples include fixed oils and ethyl oleate. A suitable carrier is 5% dextrose in saline. Frequently, it is desirable to include additives in the carrier such as buffers and preservatives or other substances to enhance isotonicity and chemical stability.

- 25 To achieve satisfactory bioavailability using formula 1 or 2 compounds, the compounds are frequently administered in the form of a hot liquid (preferably as hot as possible, such as at least 65-70 °C), e.g., dissolved in hot water. Solubility is typically enhanced at such higher temperatures, i.e., solubility at 70 °C can be about 10 times higher than solubility at 40 °C. Alternatively or additionally,
30 bioavailability can be improved by administering the compounds according to the present invention within liposomes, the manufacture of such liposomes and the insertion of active ingredients into such liposomes being well known in the art.

In the case of oral ingestion, excipients useful for solid preparations for oral administration are those generally used in the art, and the useful examples are

excipients such as lactose, sucrose, sodium chloride, starches, calcium carbonate, kaolin, crystalline cellulose, methyl cellulose, glycerin, sodium alginate, gum arabic and the like, binders such as polyvinyl alcohol, polyvinyl ether, polyvinyl pyrrolidone, ethyl cellulose, gum arabic, shellac, sucrose, water, ethanol, propanol, carboxymethyl cellulose, potassium phosphate and the like, lubricants such as magnesium stearate, talc and the like, and further include additives such as usual known coloring agents, disintegrators and the like. Examples of bases useful for the formulation of suppositories are oleaginous bases such as cacao butter, polyethylene glycol, lanolin, fatty acid triglycerides, witepsol (trademark, Dynamite Nobel Co. Ltd.) and the like. Liquid preparations may be in the form of aqueous or oleaginous suspension, solution, syrup, elixir and the like, which can be prepared by a conventional way using additives.

The dosage of any one or more of the compounds described herein which is effective in treatment against respiratory virus infections, e.g., rhinovirus or influenza infections, will depend on factors including the specific compound or combination of compounds being utilized, the mode of administration, and the organism being treated. Dosages of a particular compound or combinations of compound, each belonging to the compounds described herein, for a given host can be determined using conventional considerations; for example, by customary comparison of the differential activities of the subject compounds and of a known agent, that is, by means of an appropriate pharmacological protocol. With respect to the duration of treatment, it is typical for skilled clinicians to monitor patients in order to determine when the treatment is providing therapeutic benefit, and to determine whether to increase dosage, decrease dosage, discontinue therapy, resume therapy or alter therapy.

Further, the effectiveness of a particular regimen can be monitored by following over time the presences of viral particles in blood samples of an organism being treated. There are available commercially kits for the detection of viral antigens. It will be possible to cause a reduction, over a period of about two months, in the level of detectable p24 antigen in the blood serum of a patient by means of administration of compounds described herein. A better measure of the progression of the level of infection would be the percentage infected macrophage population. Monocytes/macrophage cells obtained from either the blood or the lung

during a course of treatment with compounds described herein will show a reduction in recoverable HIV antigen as the therapy progresses.

In one embodiment of the invention, a pharmaceutical formulation comprising any of cirsiolol, tangeretin, gossypetin, 7,8-Benzoflavone, 6-Hydroxyflavone, flavone, naringin, hesperetin, 3(4'-bromophenyl) coumarin is administered at the rate of 1 unit dose to 10 unit doses per day, and preferably 1 unit dose to 4 unit doses per day. The doses are given for periods of up to twelve weeks and in certain cases may be given for the life of the patient or depending on the patient's medical requirements at less frequent intervals.

In one embodiment of the invention, a pharmaceutical formulation comprising a compound as described herein is in combination with other anti-viral agents.

In one aspect of the invention, a unit dose comprises about 0.01 to about 5000 mg of a formula 1 or 2 compound, typically about 5-1000 mg, often about 10-500 mg, e.g., for most human applications, one will administer about 3 g/day of naringin in one or more unit or subunit dosages.

In one embodiment of the invention, the pharmaceutical formulation is administered orally in unit doses once per day when the compound is in a slow release form or in 1, 2, 3, 4, 5, 6, 7 or 8 unit doses or sub doses per day when the compound is in its native form. The pharmaceutical formulation may be administered intravenously in unit doses comprising a compound from those described herein in the range of about 0.1 mg to about 80 mg per Kg of body weight, typically about 0.5-25 mg/kg/day

In one embodiment of the invention, a pharmaceutical formulation comprising a compound from those as described herein is administered using an emulsifying or semi-emulsifying formulation to improve absorption from the small intestine. Such an emulsion may be formulated using a derivative of coconut oil e.g. Miglyol 812.

In another embodiment of the invention, the method includes the step of treating a patient with an immune system booster both prior to and/or simultaneously while a pharmaceutical formulation comprising a compound from those described herein is being administered.

The present invention is also directed to pharmaceutical formulations that contain one or more of the compounds according to the present invention together with ribavirin, alpha interferon, or both ribavirin and alpha interferon.

In some embodiments, the formula 1 or 2 compound that is present in the compositions or that is used in the methods disclosed herein is completely dissolved in aqueous or non-aqueous excipients. However, in some embodiments, e.g., transient compositions or some formulations, the formula 1 or 2 compound is partially dissolved or mixed while the remaining portion is present as a solid, which can be a suspension or a colloid. In related embodiments, the formula 1 or 2 compound is incompletely dissolved and is present as a suspension or gel.

In addition to compounds of formula 1 or 2, or their salts, the pharmaceutical compositions may contain other additives, such as pH adjusting additives, in particular, agents such as acids, bases, or buffers, including sodium lactate, sodium acetate, and sodium gluconate. Further, such compositions may contain microbial preservatives, such as methylparaben, propylparaben, benzyl alcohol and benzyl benzoate. If a multiple use vial is supplied, the pharmaceutical composition should likewise include such a microbial preservative. The formulations may be, of course, lyophilized, using techniques well known in the art.

Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the formula 1 or 2 compound; as a powder or granules; as solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The formula 1 or 2 compound may also be presented as a bolus, electuary or paste.

A tablet may be made by compression or molding, optionally with one or more excipients. Compressed tablets may be prepared by compressing in a suitable machine the formula 1 or 2 compound in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the formula 1 or 2 compound therein.

The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier, which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make up the emulsifying wax, and the wax together with the oil and fat make up the emulsifying ointment base, which forms the oily dispersed phase of the cream formulations. Emulgents and emulsion stabilizers suitable for use in formulations comprising a formula 1 or 2 compound include Tween® 60, Span® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate.

Formulations suitable for buccal administration include lozenges comprising a formula 1 or 2 compound in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the formula 1 or 2 compound in an inert basis such as gelatin and glycerin, or sucrose and acacia.

Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.

Formulations suitable for intrapulmonary or nasal administration will have a particle size for example in the range of 0.01 to 200 microns (including particle sizes in a range between 0.01 and 500 microns in increments of 0.1 microns such as 0.1, 0.2, 0.3, 0.4, 0.5, 1, 2, 5, 30 microns, 35 microns, etc.), which is administered by inhalation through the nasal passage or by inhalation through the mouth so as to reach the various bronchi or alveolar sacs. Formulations suitable for aerosol or dry powder administration may be prepared according to conventional methods and may be delivered with other therapeutic agents such as compounds heretofore used in the treatment or prophylaxis of *Trypanosome* infections. Metered dose inhalers readily administer inhalation therapy.

Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the formula 1 or 2 compound such carriers or excipients as are known in the art to be appropriate.

Formulations suitable for parenteral administration are sterile and include aqueous and non-aqueous injection solutions which may contain anti-oxidants,

buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials with elastomeric stoppers, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described. Unit dosage formulations will typically contain a daily dose or unit daily sub-dose, as recited above, or an appropriate fraction thereof, of a formula 1 or 2 compound.

To the extent not already indicated, it will be understood by those of ordinary skill in the art that any one of the various specific embodiments herein described and illustrated may be further modified to incorporate features shown in any of the other embodiments disclosed herein.

The invention provides veterinary compositions comprising at least one formula 1 or 2 compound together with a veterinary carrier. Also, the formula 1 or 2 compound may be present in the animal's feed or water. Excipients for veterinary applications may include compounds, e.g., small amounts of chloroform, that may not be generally suitable for human use. Many of the formula 1 or 2 compounds are soluble in organic solvents, e.g., many of the coumarins are soluble in chloroform, acetone or DMF.

Veterinary carriers are materials useful for the purpose of administering the composition to cats, dogs, horses, mice, rats, hamsters, rabbits and other animals and may be solid, liquid or gaseous materials that are otherwise inert or acceptable in the veterinary art and are compatible with the formula 1 or 2 compound. These veterinary compositions may be administered orally, parenterally or by any other desired route, e.g., as described herein.

Applications. The compositions and formulations disclosed herein are useful in the treatment of, or ameliorate one or more symptoms associated with, the conditions or infections disclosed herein. These compositions and formulations may also be used to treat, or ameliorate one or more symptoms associated with or caused by, a retroviral infection such as a HIV1 or HIV2 infection in humans. As used herein, phrases such as "amelioration of one or more symptoms associated

with" means that such compounds or formulations may be used to reduce replication of an infectious agent or to reduce the number of infectious agents that are present in a subject or to ameliorate one or more symptoms associated with, or caused by, the condition or infection (e.g., reduced fever, a shortened duration of, or reduced level of, pain, or a noticeable reduction of or elimination of diarrhea, fatigue or involuntary weight loss (e.g., weight loss of more than about 4-5% of body weight over a relatively short time period).

Exemplary viral infections that are included in the invention for treatment, prophylaxis or amelioration of one or more symptoms using an effective amount of a formula 1 or 2 compound include Central European encephalitis virus, Chikungunya virus, Congo-Crimean hemorrhagic fever virus, Dengue viruses 1-4, Eastern equine encephalitis virus, Echoviruses 1-9 and 11-27 and 29-34, Enteroviruses 68-71, Epstein-Barr virus (human herpesvirus 4), Hantaan virus, human Hepatitis A virus, human Hepatitis B virus, human Hepatitis C virus, human herpes simplex viruses 1 and 2, human enteric coronavirus, human cytomegalovirus (human herpesvirus 5), human herpesviruses 6A, 6B, and 7, human immunodeficiency viruses 1 and 2, human respiratory coronaviruses 229E and OC43, human T-lymphotropic viruses 1 and 2, HTLV/BLV viruses, influenza viruses A and B, Japanese encephalitis virus, Kyasanur forest virus, La Crosse virus, Lassa virus, Mayaro virus, Measles virus, Mumps virus, Murray Valley encephalitis virus, Norwalk and related viruses, O'nyong-nyong virus, Omsk hemorrhagic fever virus, Oropouche virus, Papillomaviruses 1-60, Parainfluenza viruses 1, 2, 3 or 4, Parvoviruses, Parvovirus B-19, Polioviruses 1, 2 or 3, RA-1 virus, *Picornavirus* genus viruses, Rabies virus, Respiratory syncytial virus, Rhinoviruses 1-113, Rift Valley fever virus, Rocio virus, Ross River virus, Rubella virus, Russian spring-summer encephalitis virus, Sandfly fever-Naples virus, Sandfly fever-Sicilian virus, St. Louis encephalitis virus, SV 40 virus, Tahyna virus, Vaccinia virus, Varicella-zoster virus (human herpesvirus 3), Variola virus, Venezuelan equine encephalitis virus, Vesicular stomatitis viruses, West Nile virus, Eastern equine encephalitis virus, Yellow fever virus, Avian reticuloendotheliosis virus, Avian sarcoma and leukosis viruses, B virus (*Cercopithecus* herpesvirus), Berne virus (horses), Border disease virus (sheep), Bovine enteroviruses 1-7, Bovine ephemeral fever virus, Bovine immunodeficiency virus, Bovine leukemia virus, Bovine mamillitis virus, Bovine papillomaviruses, Bovine papular stomatitis

virus, Bovine respiratory syncytial virus, Bovine virus diarrhea virus, Breda virus (calves), Canine adenovirus 2, Canine distemper virus, Canine parvovirus, Caprine arthritis-encephalitis virus, Eastern equine encephalitis virus, Encephalomyocarditis virus, Equine abortion virus, Equine adenoviruses, Equine coital exanthema virus, Equine infectious anemia virus, Equine rhinopneumonitis virus (EHV4), Feline immunodeficiency virus, Feline infectious peritonitis virus, Feline panleukopenia virus, Feline sarcoma and leukemia viruses, Foot-and-mouth disease viruses, Hemagglutinating encephalomyelitis virus (swine), Hog cholera virus, Infectious bovine rhinotracheitis virus, Infectious bronchitis virus (fowl), Infectious canine hepatitis virus, Infectious hematopoietic necrosis virus (fish), Infectious laryngotracheitis virus (fowl), Influenza viruses of swine, horses, seals, and fowl, Japanese encephalitis virus, Maedi/visna virus (sheep), Marek's disease virus (fowl), Mink enteritis virus, Minute virus of mice, Mouse hepatitis viruses, Mouse mammary tumor virus, Mouse poliomyelitis virus (Theiler's virus), Mucosal disease virus (cattle), Newcastle disease virus (fowl), Parainfluenza virus 3, Parainfluenza virus 1 (Sendai virus), Peste-des-petits-ruminants virus (sheep and goats), Pneumonia virus of mice, Progressive pneumonia virus of sheep, Pseudorabies virus, Rabies virus, Rift Valley fever virus, Rinderpest virus, Rotaviruses, Shope papillomavirus, Simian immunodeficiency viruses (SIV, SHIV), Swine vesicular disease virus, Tick-borne encephalitis viruses, Transmissible gastroenteritis virus (swine), Turkey bluecomb virus, Venezuelan equine encephalitis virus, Vesicular stomatitis viruses, Wesselsbron virus and Western equine encephalitis virus. The compounds disclosed herein, e.g., as named in numbered embodiment 35 or in any of the claims, can be used for any of these infections or conditions.

Compounds of formula 1 or 2, including ones that are new compounds *per se*, are useful for treating or preventing bacterial, mycoplasma, fungal or yeast infections, e.g., gram positive or gram negative bacteria infections, or for ameliorating one or more symptoms associated with such infections. Exemplary infections include ones caused by isolates, species, strains or variants of the *Bartonella*, *Bordetella*, enterotoxigenic, enteropathogenic, enteroinvasive or enterohemorrhagic *Escherichia*, *Haemophilus*, *Helicobacter*, *Mycobacterium*, *Listeria*, *Neisseria*, *Pseudomonas*, *Salmonella*, *Shigella*, *Staphylococcus*, *Streptococcus*, *Vibrio*, *Yersinia*, *Aspergillus*, *Candida* or *Cryptococcus* taxonomic

groups. Such infections may occur concomitantly with a viral or parasite infection, e.g., as described herein, or they may be not be accompanied by any apparent or diagnosed viral or parasite infection.

All references cited herein are incorporated herein by reference in their entirety.

Enumerated embodiments. Aspects of the invention include the following enumerated embodiments, which further illustrate the invention and aspects thereof or related subject matter. In general, any of the compounds disclosed herein is suitable for use in any of the clinical conditions or infections disclosed herein.

1. A method of treatment of a patient suffering from a viral infection (e.g., a retrovirus, a respiratory virus or a hepatitis C virus infection) or having a common cold, comprising administering to said patient an effective amount of at least one compound of formula 1 or 2.

2. A method according to embodiment 1, wherein said at least one compound is naringin, naringenin or a derivative (e.g., an ester) that can convert to either *in vivo*.

3. A method of reducing at least one aminotransferase level in a patient suffering from hepatitis virus C, comprising administering to said patient an effective amount of at least one compound of formula 1 or 2.

4. A method according to embodiment 3, wherein said at least one compound is one or more of cirsiolol, tangeretin, gossypetin, naringenin, naringin or a derivative of any of these compounds that can convert *in vivo* to cirsiolol, tangeretin, gossypetin, naringenin or naringin.

5. A method of treatment of a patient suffering from a togavirus, comprising administering to said patient an effective amount of at least one compound of formula 1 or 2.

6. A method according to embodiment 5, wherein said at least one compound is one or more of cirsiolol, tangeretin, gossypetin, naringenin, naringin or a derivative of any of these compounds that can convert *in vivo* to cirsiolol, tangeretin, gossypetin, naringenin or naringin.

7. A method according to embodiment 5, wherein said togavirus is an alphavirus.

8. A method according to embodiment 5, wherein said togavirus is a

flavivirus.

9. A method according to embodiment 8, wherein said flavivirus is hepatitis G.

5 10. A method according to embodiment 8, wherein said flavivirus is yellow fever.

11. A method according to embodiment 5, wherein said togavirus is a rubivirus.

12. A method according to embodiment 11, wherein said rubivirus is rubella.

10 13. A method according to embodiment 5, wherein said togavirus is a pestivirus.

14. A method according to embodiment 13, wherein said pestivirus is BVDV.

15 15. A method according to any of embodiments 1 - 14, further comprising administering to said patient ribavirin and/or alpha interferon.

16. A pharmaceutical composition comprising (a) at least one compound of formula 1 or 2 and (b) ribavirin and/or alpha interferon.

20 17. A method of preventing disease caused by one or more liver parasite and/or minimizing the likelihood of onset of disease caused by one or more liver parasite and/or minimizing the adverse effects of future contact with one or more liver parasite, comprising administering to a patient an effective amount of at least one compound of formula 1 or 2.

25 18. A method according to embodiment 17, wherein said at least one compound is one or more of cirsiolol, tangeretin, gossypetin, naringenin, naringin or a derivative of any of these compounds that can convert *in vivo* to cirsiolol, tangeretin, gossypetin, naringenin or naringin.

30 19. A method of (1) treating a patient suffering from malaria (e.g., *Plasmodium falciparum* or *Plasmodium vivax*, where the Plasmodium parasite is drug [e.g., chloroquine] resistant or drug sensitive) or (2) ameliorating one or more symptoms associated with malaria, comprising administering to said patient an effective amount of at least one compound of formula 1 or 2.

20. A method according to embodiment 19, wherein said at least one compound is one or more of cirsiolol, tangeretin, gossypetin, naringenin, naringin or a derivative of any of these compounds that can convert *in vivo* to cirsiolol, tangeretin, gossypetin, naringenin or naringin.

21. A method of prophylactic treatment of a patient against malaria, comprising administering to said patient an effective amount of at least one compound of formula 1 or 2.

22. A method according to embodiment 21, wherein said at least one
5 compound is one or more of cirsiolol, tangeretin, gossypetin, naringenin, naringin or a derivative of any of these compounds that can convert *in vivo* to cirsiolol, tangeretin, gossypetin, naringenin or naringin.

23. A method of treatment of a patient suffering from common cold, comprising administering to said patient an effective amount of at least one
10 compound of formula 1 or 2.

24. A method according to embodiment 23, wherein said at least one compound is naringin, naringenin or a derivative (e.g., an ester) that can convert to either *in vivo*.

25. A method according to embodiment 23 or embodiment 24, wherein said
15 administering is through nasal route.

26. A method of prophylactic treatment of a patient against common cold, comprising administering to said patient an effective amount of at least one compound of formula 1 or 2.

27. A method according to embodiment 26, wherein said at least one
20 compound is one or more of cirsiolol, tangeretin, gossypetin, naringenin, naringin or a derivative of any of these compounds that can convert *in vivo* to cirsiolol, tangeretin, gossypetin, naringenin or naringin.

28. A method according to embodiment 23 or embodiment 24, wherein said administering is through nasal route.

25 29. A method of treatment of a patient suffering from influenza, comprising administering to said patient an effective amount of at least one compound of formula 1 or 2.

30. A method according to embodiment 29, wherein said at least one
30 compound is one or more of cirsiolol, tangeretin, gossypetin, naringenin, naringin or a derivative of any of these compounds that can convert *in vivo* to cirsiolol, tangeretin, gossypetin, naringenin or naringin.

31. A method according to embodiment 29 or embodiment 30, wherein said administering is through nasal route.

32. A method of prophylactic treatment of a patient against influenza,

comprising administering to said patient an effective amount of at least one compound of formula 1 or 2.

33. A method according to embodiment 32, wherein said at least one compound is one or more of cirsiolol, tangeretin, gossypetin, naringenin, naringin or
5 a derivative of any of these compounds that can convert *in vivo* to cirsiolol, tangeretin, gossypetin, naringenin or naringin.

34. A method according to embodiment 32 or embodiment 33, wherein said administering is through nasal route.

35. The method of any of embodiments 1-34 wherein the formula 1 or 2
10 compound is acacetin [reg. no. 480-44-4], apigenin [reg. no. 520-36-5], apiin [reg. no. 26544-34-3], baicalein [reg. no. 491-67-8], baicalein trimethyl ether [5,6,7-trimethoxyflavone], 5,6-benzoflavone [reg. no. 6051-87-2], 7,8-benzoflavone [reg. no. 604-59-1], 8-carboxy-3-methylflavone [reg. no. 3468-01-7], dihydrorobinetin [reg. no. 4382-33-6], 3,7-dihydroxy-3',4'-dimethoxyflavone [fisetin 3'4'-
15 dimethylether], 3,5-dihydroxyflavone [reg. no. 6665-69-6], 3,6-dihydroxyflavone, 3,7-dihydroxyflavone [reg. no. 492-00-2], 3,2'-dihydroxyflavone, 3,3'-dihydroxyflavone, 5,7-dihydroxyflavone [chrysin], 5,2'-dihydroxyflavone, 5,3'-dihydroxyflavone, 5,4'-dihydroxyflavone, 6,7-dihydroxyflavone [reg. no. 38183-04-9], 6,2'-dihydroxyflavone, 6,3'-dihydroxyflavone, 6,4'-dihydroxyflavone,
20 7,8-dihydroxyflavone, 7,2'-dihydroxyflavone, 7,3'-dihydroxyflavone, 7,4'-dihydroxyflavone, 2',3'-dihydroxyflavone, 2'4'-dihydroxyflavone, 3',4'-dihydroxyflavone [4-hydroxyflavanol], 5',6'-dihydroxy-7-methoxyflavone [reg. no. 29550-13-8], 5',4'-dihydroxy-7-methoxyflavone [reg. no. 437-64-9], 3',4'-dihydroxy- α -naphthoflavone, 3',4'-dihydroxy- β -naphthoflavone,
25 5',8'-dihydroxy-3,7,3',4'-tetramethoxyflavone [reg. no. 7380-44-1], gossypetin 3,7,3'4'-tetramethylether], 3,7'-dihydroxy-3,4,5'-trimethoxyflavone [robinetin trimethylether], 5,3'-dihydroxy-6,7,4'-trimethoxyflavone [eupatorin], 3,5'-dimethoxyflavone, 3,6-dimethoxyflavone, 3,7'-dimethoxyflavone, 3,2'-dimethoxyflavone, 3,3'-dimethoxyflavone, 3,4'-dimethoxyflavone,
30 5,7-dimethoxyflavone [reg. no. 21392-57-4 chrysin dimethylether], 5,2'-dimethoxyflavone, 5,3'-dimethoxyflavone, 5,4'-dimethoxyflavone, 6,7'-dimethoxyflavone, 6,2'-dimethoxyflavone, 6,3'-dimethoxyflavone, 6,4'-dimethoxyflavone, 7,8'-dimethoxyflavone, 7,2'-dimethoxyflavone, 7,3'-dimethoxyflavone, 7,4'-dimethoxyflavone, 2,3'-dimethoxyflavone,

- 2,4'-dimethoxyflavone, 3,4'-dimethoxyflavone, 3-hydroxy-3,4'-dimethoxyflavone, 3,4'-dimethoxy- α -naphthoflavone, 3,4'-dimethoxy- β -naphthoflavone, 6,7'-dimethoxy-5,3',4'-trihydroxyflavone [reg. no. 34334-69-5; cirsiol], 3,4'-dimethoxy-5,7',3'-trihydroxyflavone [reg. no. 33429-83-3], diosmetin [reg. no. 520-34-3], diosmetin-7-rutinoside [reg. no. 520-27-4; diosmin], eupatorin-5-methyl ether [3'-hydroxy-4',5,6,7-tetramethoxyflavone], 3,7,3',4'-tetrahydroxyflavone [reg. no. 528-43-31; fisetin], flavone [reg. no. 525-82-6], fortunellin [reg. no. 20633-93-6], 3,5,7-trihydroxyflavone [reg. no. 548-83-4; galangin], 6,7,8,3',4',5'-hexamethoxy-5-hydroxyflavone [reg. no. 21187-73-5; gardenin A], geraldol [reg. no. 21511-25-1], 3,5,6,7,3',4'-hexahydroxyflavone [gossypetin], 3,5,7,8,3',4'-hexahydroxyflavone-8-glucoside [gossypin], 5,6,7,3',4',5'-hexamethoxyflavone [reg. no. 29043-07-0], 6-hydroxyapigenin [reg. no. 529-53-3; scutellarein], 3-hydroxy-6,4'-dimethoxyflavone, 5-hydroxy-7,4'-dimethoxy-6,8-dimethylflavone [reg. no. 3122-88-1; eucalyptin], 3-hydroxyflavone [reg. no. 577-85-5; flavonol], 5-hydroxyflavone [reg. no. 491-78-1; primuletin], 6-hydroxyflavone [reg. no. 6665-83-4], 7-hydroxyflavone [reg. no. 6665-86-7], 2'-hydroxyflavone, 3'-hydroxyflavone, 4'-hydroxyflavone, 3-hydroxy-5-methoxyflavone, 3-hydroxy-6-methoxyflavone, 3,4'-dihydroxy-6-methoxyflavone, 3-hydroxy-7-methoxyflavone [reg. no. 7478-60-6; 7-methoxyflavanol], 3-hydroxy-2'-methoxyflavone, 3-hydroxy-3'-methoxyflavone, 6'-hydroxy-7-methoxyflavone, 6'-hydroxy-2'-methoxyflavone, 6'-hydroxy-3'-methoxyflavone, 6'-hydroxy-4'-methoxyflavone, 7'-hydroxy-2'-methoxyflavone, 7'-hydroxy-3'-methoxyflavone, 7'-hydroxy-4'-methoxyflavone [pratol], 5'-hydroxy-7-methoxyflavone, 4'-hydroxy-5-methoxyflavone, 4'-hydroxy-6-methoxyflavone, 2'-hydroxy- α -naphthoflavone, 2'-hydroxy- β -naphthoflavone, 4'-hydroxy- α -naphthoflavone, 4'-hydroxy- β -naphthoflavone, 5-hydroxy-3,3',4',7-tetramethoxyflavone [reg. no. 1254-15-4; quercetin tetramethylether], 3'-hydroxy-5,6,7,4'-tetramethoxyflavone [reg. no. 21764-09-0], isoquercitrin [reg. no. 21637-25-2; quercetin-3-glucoside], isorhamnetin [reg. no. 418-19-3], isorhamnetin-3-glucoside, isorhamnetin-3-rutinoside [reg. no. 604-80-8; narcisin], kaempferol [reg. no. 520-180-3; 3,5,7,4'-tetrahydroxyflavone], kaempferol-3,7,4'-trimethyl ether [reg. no. 15486-34-7], karanjin 521-88-0], luteolin [reg. no. 491-70-3], luteolin-4'-glucoside [reg. no. 62920-38-3], luteolin-7-glucoside [reg. no. 5373-11-5], 4'-methoxy-5,6-benzoflavone, 3-methoxyflavone [reg. no.

7245-02-5], 5-methoxyflavone [reg. no. 42079-78-7], 6'-methoxyflavone 26964-24-9], 7-methoxyflavone [reg. no. 222395-22-8], 2'-methoxyflavone [reg. no. 19725-47-4], 3'-methoxyflavone, 4'-methoxyflavone [reg. no. 4143-74-2], 5-methoxyflavone, 3-hydroxy-5-methoxyflavone, 6-methoxyflavone [reg. no. 26964-24-9], 3-hydroxy-6-methoxyflavone, 4'-methoxyflavone [reg. no. 7478-60-6], 3-hydroxy-7-methoxyflavone, 6-methoxyluteolin, 2'-methoxy- α -naphthoflavone [2'-methoxy-7,8-benzoflavone], 2'-methoxy- β -naphthoflavone [2'-methoxy-5,6-benzoflavone], 4'-methoxy- α -naphthoflavone, 4'-methoxy- β -naphthoflavone, 6-methylflavone [reg. no. 29976-75-8], 8-methylflavone, 6-methyl-4'-methoxyflavone, 8-methyl-4'-methoxyflavone, morin dihydrate [reg. no. 480-16-0], myricetin [reg. no. 529-44-2; 3,5,7,3',4',5'-hexahydroxyflavone], myricetin-3-rhamnoside [reg. no. 17912-87-72], naringin, naringenin, neodiosmin [diosmetin-7-neohesperidioside], 3,7,3',4',5'-pentamethoxyflavone [reg. no. 490-31-3; robinetin], 3,7,3',4',5'-pentahydroxyflavone, 5,6,7,3',4'-pentamethoxyflavone [reg. no. 2306-27-6; sinensetin], 3,6,7',3',4'-pentamethoxyflavone, 5,7,3',4',5'-pentamethoxyflavone, quercetagenin [reg. no. 90-18-6], quercitrin [reg. no. 522-12-3; quercitrin-3-rhamnoside], 3,5,7,3',4'-pentamethoxyflavone [reg. no. 1247-97-8; quercetin 3,5,7,3',4'-pentamethyl ether], 3,7,3',4'-tetramethoxyflavone [reg. no. 1245-15-4; retusin; quercetin-3,7,3',4'-tetramethyl ether], rutin trihydrate [reg. no. 153-18-4], 5,6,7,4'-tetramethoxyflavone [reg. no. 1168-42-9; scutellarein tetramethyl ether], spiraeoside [reg. no. 20229-56-5], tangeretin [reg. no. 481-53-8], 3,5,7,4'-tetrahydroxy-3',5'-dimethoxyflavone [reg. no. 4423-37-4; syringetin], 3,5,3',4'-tetrahydroxy-7-methoxyflavone 90-19-7; rhamnetin], 7,8,3',4'-tetrahydroxyflavone, 5,7,3',4'-tetramethoxyflavone [reg. no. 855-97-0; luteolin tetramethyl ether], 7,8,3',4'-tetramethoxyflavone [reg. no. 855-97-0], 3,6,4'-trihydroxyflavone, 3,7,4'-trihydroxyflavone [reg. no. 2034-65-3; 5-deoxykampferol], 3,3',4'-trihydroxyflavone, 5,7,8-trihydroxyflavone [reg. no. 4443-09-8], 5,7,2'-trihydroxyflavone [reg. no. 73046-40-9], 5,3',4'-tetrahydroxy-3',5'-dimethoxyflavone [reg. no. 4423-37-4], 6,3',4'-trihydroxyflavone, 7,8,2'-trihydroxyflavone, 7,8,3'-trihydroxyflavone, 7,8,4'-trihydroxyflavone, 7,3',4'-trihydroxyflavone [reg. no. 2150-11-0], 3,5,7-trihydroxy-3',4',5'-trimethoxyflavone [myricetin trimethyl ester], 5,7,4'-trihydroxyflavone [reg. no. 5631-70-9], 3,5,7-trimethoxyflavone, vitexin-2''-O-rhamnoside [reg. no. 64820-99-1], 2-(3,4-dibenzyloxy)-4,5,6-

- trimethoxyacetophenone, 3',4'-dibenzoyloxy-2-hydroxy-4,5,6-trimethoxydibenzoylmethane, 3',4'-dibenzoyloxy-5,6,7-trimethoxyflavone, 3',4'-dihydroxy-5,6,7-trimethoxyflavone, 3',4'-diacetoxy-5,6,7-trimethoxyflavone, 3-(4'-bromophenyl)-6-methoxycoumarin, 3-(4'-bromophenyl)-7-methoxy-4-methyl coumarin, 3-(4'-bromophenyl)-7-methoxy-4-phenyl coumarin, 3-(4'-bromophenyl) coumarin, 3-(4'-bromophenyl)-6,8-dichloro-4-methyl coumarin, 3-(4'-bromophenyl)-7-hydroxy-4-methyl coumarin, 6-bromo-3-(4'-chlorophenyl)-4-methyl coumarin, 6-bromo-4-(4'-chlorophenyl)-3-phenyl coumarin, 6-bromo-3,4-di-(4'-chlorophenyl) coumarin, 6-bromo-3-(2,4-dichlorophenyl)-4-methyl coumarin, 6-bromo-3,4-diphenylcoumarin, 6-methoxy-4-methylcoumarin, 6-methoxy-4-methyl-3-phenylcoumarin, 7-methoxy-4-methyl-3-phenyl coumarin, 6-methoxy-3-(4'-nitrophenyl) coumarin, 6-bromo-3-(4'-methoxyphenyl)-4-methyl coumarin, 3-(4'-bromophenyl)-6-chloro-4,7-dimethyl coumarin, 3-(4'-bromophenyl)-6-chloro-4-methyl coumarin, 6-chloro-3-(2-chlorophenyl)-4-methylcoumarin, 6-chloro-3-(4'-chlorophenyl)-4-methyl coumarin, 3-(4'-methoxyphenyl)-4-methyl coumarin, 6-methyl-3-(4-methoxyphenyl)-4-phenyl coumarin, 3-(4'-nitrophenyl) coumarin, 6-methoxy-3-(4-methoxyphenyl)-4-methylcoumarin, 7-methoxy-3-(4'-methoxyphenyl)-4-methylcoumarin, 7-methoxy-3-(4'-methoxyphenyl)-4-phenylcoumarin, 3-(4'-methoxyphenyl)coumarin, 6-methoxy-3-phenyl coumarin, 7-methoxy-3-phenyl coumarin, 6,8-dichloro-3-2,4-dichlorophenyl)-4-phenylcoumarin, 6,8-dichloro-3,4-diphenyl coumarin, 6,8-dichloro-3-(4'methoxyphenyl)-4-methyl coumarin, 6,8-dichloro-3-(4'methoxyphenyl)-4-phenyl coumarin, 3-(2,4-dichlorophenyl)coumarin, 3-(2,4-dichlorophenyl)-4,6-dimethyl coumarin, 3-(2,4-dichlorophenyl)-7-ethoxycoumarin, 3-(2,4-dichlorophenyl)-7-hydroxy coumarin, 3-(2,4-dichlorophenyl)-6-hydroxy-4-methylcoumarin, 3-(2,4-dichlorophenyl)-7-hydroxy-4-methylcoumarin, 3-(2,4-dichlorophenyl)-6-ethoxy-4-methyl coumarin, 3-(2,4-dichlorophenyl)-7-ethoxy-4-methylcoumarin, 3-(2,4-dichlorophenyl)-7-ethoxy-4-phenylcoumarin, 3-cyano-6-methoxycoumarin, 3-cyano-7-methoxy coumarin, 6, 8-dichloro-3-(2,4-dichlorophenyl)-4-methylcoumarin, 3-(4'-chlorophenyl)-4-methylcoumarin,

- 3-cyano-7-ethoxy coumarin, 3-cyano-7-hydroxycoumarin,
3-cyano-7-hydroxy-4-methylcoumarin, 3-
(2-chlorophenyl)-7-methoxy-4-phenylcoumarin, 3-
(4'-chlorophenyl)-7-methoxy-4-phenyl coumarin, 3-
5 (2-chlorophenyl)-4-methylcoumarin, 3-(2-chlorophenyl)-7-methoxycoumarin, 3-
(4'-chlorophenyl)-7-methoxy coumarin, 3-
(2-chlorophenyl)-7-methoxy-4-methylcoumarin, 3-
(4'-chlorophenyl)-7-methoxy-4-methyl coumarin, 3-
(2-chlorophenyl)-7-hydroxy-4-phenylcoumarin, 3-
10 (4'-chlorophenyl)-7-hydroxy-4-phenyl coumarin, 3-(4'-chlorophenyl)-6-methoxy
coumarin, 3-(4'-chlorophenyl)-7-hydroxycoumarin, 3-
(2-chlorophenyl)-7-hydroxy-4-methylcoumarin, 3-
(4'-chlorophenyl)-7-hydroxy-4-methyl coumarin, 3-
(2-chlorophenyl)-7-ethoxy-4-methylcoumarin, 3-
15 (2-chlorophenyl)-7-ethoxy-4-phenylcoumarin, 3-
(2-chlorophenyl)-7-hydroxycoumarin, 4-(4-chlorophenyl)-3-
(2,4-dichlorophenyl)-6-methylcoumarin, 3-(2-chlorophenyl)-4,6-dimethylcoumarin,
3-(2-chlorophenyl)-7-ethoxycoumarin, 3-(4'-chlorophenyl)-7-ethoxycoumarin, 3-
(2-chlorophenyl)-6,8-dichloro-4-methylcoumarin, 3-
20 (4'-chlorophenyl)-6,8-dichloro-4-methyl coumarin, 4-
(4'-chlorophenyl)-6,8-dichloro-3-phenyl coumarin, 6-chloro-3-
(4'-methoxyphenyl)-4-phenyl coumarin, 6-chloro-4-methyl-3-(4'-nitrophenyl)
coumarin, 3-(2-chlorophenyl) coumarin, 7-hydroxy-3-
(4'-methoxyphenyl)-4-methylcoumarin, 7-hydroxy-3-(4'-methoxyphenyl)-4-phenyl
25 coumarin, 6-hydroxy-4-methyl-3-phenylcoumarin, 6-ethoxy-4-methylcoumarin,
6-ethoxy-4-methyl-3-phenyl coumarin, 7-hydroxy-3-(4'-methoxyphenyl) coumarin,
6-hydroxy-3-(4-methoxyphenyl)-4-methylcoumarin, 6-ethoxy-3
(4-methoxyphenyl)-4-methylcoumarin, 7-ethoxy-3-(4'-methoxyphenyl)-4-methyl
coumarin, 7-ethoxy-3-(4'-methoxyphenyl)-4-phenyl coumarin, 4,6-dimethyl-3-
30 (4-methoxyphenyl)coumarin, 3,4-diphenyl-7-methoxy coumarin,
3,4-diphenyl-6-methyl coumarin, 7-ethoxy-3-(4'-methoxyphenyl) coumarin,
3,4-diphenyl-7-hydroxy coumarin, 3-
(2,4-dichlorophenyl)-7-hydroxy-4-phenylcoumarin, 3-
(2,4-dichlorophenyl)-7-methoxycoumarin, 3-

- (2,4-dichlorophenyl)-6-methoxy-4-methylcoumarin, 3-(2,4-dichlorophenyl)-7-methoxy-4-methylcoumarin, 3-(2,4-dichlorophenyl)-7-methoxy-4-phenylcoumarin, 3-(2,4-dichlorophenyl)-4-methylcoumarin, 6-chloro-3-formyl-7-methylcoumarin,
- 5 6-chloro-3(4'-methoxyphenyl)-4-methyl coumarin, 6-chloro-3(4'-methoxyphenyl)-7-methyl-4-phenyl coumarin, 6-chloro-4,7-dimethyl-3(4'-methoxy phenyl) coumarin, 6-chloro-3,4-diphenyl coumarin, 6-chloro-3,4-diphenyl-7-methyl coumarin, 6-chloro-3,4-di(4'-chlorophenyl)-7-methyl coumarin, 6-chloro-3
- 10 (2,4-dichlorophenyl)-7-methyl-4-phenylcoumarin, 6-chloro-3(2,4-dichlorophenyl)-4-phenylcoumarin, 6-chloro-3(2-chlorophenyl)-7-methyl-4-phenylcoumarin, 6-chloro-3(2-chlorophenyl)-4-phenylcoumarin, 6-chloro-4(4'-chlorophenyl)-3-phenyl coumarin, 6-chloro-3,4-di(4'-chlorophenyl) coumarin, 6-chloro-3-
- 15 (2,4-dichlorophenyl)-4,7-dimethyl coumarin, 6-chloro-3(2,4-dichlorophenyl)-4-methylcoumarin, 6-chloro-3(4'-chlorophenyl)-4,7-dimethylcoumarin, 6-chloro-4-(4'-chlorophenyl)-3(4'methoxy phenyl)coumarin, 6-chloro-4-(4'-chlorophenyl)-3-(4'methoxy phenyl)-7-methylcoumarin, 6-chloro-4-(4-chlorophenyl)-3-
- 20 (2,4-dichlorophenyl)coumarin, 6-chloro-4-(4-chlorophenyl)-3(2,4-dichlorophenyl)-7-methylcoumarin, 6-chloro-3(2-chlorophenyl)-4,7-dimethylcoumarin, 6-chloro-3(2-chlorophenyl)-4-methylcoumarin, 6-chloro-3-(4'-chlorophenyl)-4-methyl coumarin, 7-hydroxy-4-methyl-3-phenyl coumarin, 7-hydroxy-3-phenyl coumarin,
- 25 6-methoxy-3-(4'-methoxyphenyl) coumarin or 7-methoxy-3-(4'-methoxyphenyl) coumarin.

36. The method of any of embodiments 1-35 further comprising administering one or more known anti-infective or therapeutic agents, e.g., an analgesic (aspirin, acetaminophen, etc.), a compound selected from nucleoside
- 30 analogs (AZT, 3TC, ddI, ddC, D4T, etc.), protease inhibitors (indinavir, crixivan, nelfinavir), chloroquine, ribavirin, amanditine, rimantadine, oseltamivir, zanamivir, IL-2, γ -interferon and α -interferon, wherein the anti-infective or therapeutic agent is administered simultaneously (within about 2 hours of administration of the formula 1 or 2 compound) or before (at least about 4-48 hours before administration of the

formula 1 or 2 compound) or after (at least about 4-48 hours after administration of the formula 1 or 2 compound) administration of the formula 1 or 2 compound.

37. A product produced by the process of contacting a formula 1 or 2 compound and an excipient.

5 38. Use of a compound of formula 1 or 2 to prepare a medicament for use to treat or prevent an infection or to ameliorate one or more symptoms associated with an infection in a subject.

39. The use of embodiment 38 wherein the formula 1 or 2 compound is a compound named in embodiment 35.

10 40. The use of embodiment 38 or 39 wherein the infection is a viral infection or a parasite infection.

41. The use of embodiment 40 wherein the subject is a human.

42. The use of embodiment 38, 39, 40 or 41 wherein the formula 1 or 2 compound is cirsiolol or a derivative that can convert to cirsiolol *in vitro* or *in vivo*.

15 43. The use of embodiment 42 wherein the subject has a common cold.

44. A method comprising administering to a subject having an infection an effective amount of a composition comprising an acceptable excipient and one or more compounds of formula 1 or 2.

20 45. The method of embodiment 44 wherein 1, 2, 3, 4, 5 or 6 R₈ are independently selected moieties other than hydrogen, i.e., they are not hydrogen.

46. The method of embodiment 44 or 45 wherein R₈ are independently selected -OH, halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, glucuronide, a moiety that can hydrolyze to hydroxyl, a C₁₋₂₅ fatty acid, glucoside, or a group having structure (B) or (C).

25 47. The method of embodiment 44, 45 or 46 wherein the infection is a virus infection, which is optionally selected from the group consisting of a respiratory syncytial virus infection, a paramyxoviridae family virus infection, an orthomyxovirus infection, an influenza virus infection, a parainfluenza virus infection, a retrovirus infection, a hepatitis virus infection, a rhinovirus infection, a
30 pneumovirus infection, a herpesvirus infection, an enterovirus infection or a coronavirus infection.

48. The method of embodiment 44, 45 or 46 wherein the infection is a parasite infection, which is optionally selected from the group consisting of toxoplasmosis parasite, trypanosome parasite and plasmodium parasite infections.

49. The method of embodiment 47 or 48 wherein the formula 1 or 2 compound is a compound named in embodiment 35.

50. A method of treating or preventing the common cold or of ameliorating one or more symptoms of a common cold comprising administering to a subject having a common cold or susceptible to a common cold an effective amount of a composition comprising a pharmaceutically acceptable carrier and a compound or formula 1 or 2.

51. The method of embodiment 50 wherein the formula 1 or 2 compound is cirsiolol or a derivative of cirsiolol than can convert to cirsiolol *in vitro* or *in vivo*.

52. The method of embodiment 50 or 51 wherein the subject has a rhinovirus infection.

53. A method to decrease expression of TNF, IL-1 or IL-2 in a subject having an common cold or influenza infection comprising administering to the subject an effective amount of a formula 1 or 2 compound or a derivative thereof than can convert to the formula 1 or 2 compound *in vitro* or *in vivo*, wherein the modulation is detectably enhanced expression of TNF, IL-1 or IL-2.

54. The method of embodiment 53 wherein the infection is a common cold.

55. The method of embodiment 54 wherein the formula 1 or 2 compound is cirsiolol or a derivative thereof than can convert to cirsiolol *in vitro* or *in vivo*.

56. A method of treating or preventing an infection caused by a virus in the *Picornavirus* genus comprising administering to a subject having or susceptible to a *Picornavirus* infection an effective amount of a composition comprising a pharmaceutically acceptable carrier and a compound or formula 1 or 2.

57. The method of embodiment 56 wherein the formula 1 or 2 compound is cirsiolol or a derivative of cirsiolol than can convert to cirsiolol *in vitro* or *in vivo*.

58. The method of embodiment 56 or 57 wherein the subject has an infection caused by a rhinovirus, a poliovirus, a cardiovirus, a parechovirus, a hepatovirus, an enterovirus or an aphthovirus.

59. The method of embodiment 56 wherein the formula 1 or 2 compound is one or more of cirsiolol, tangeretin, gossypetin, naringenin, naringin or a derivative of any of these compounds that can convert *in vivo* to cirsiolol, tangeretin, gossypetin, naringenin or naringin.

60. A method of treating, preventing or ameliorating one or more symptoms associated with a viral or parasite infection in a subject comprising administering to the subject a formula 1 or 2 compound, which is optionally one or more of cirsiolol, tangeretin, gossypetin, naringenin, naringin or a derivative of any of these compounds that can convert to the formula 1 or 2 compound or to cirsiolol, tangeretin, gossypetin, naringenin or naringin,

wherein the viral or parasite infection is a toxoplasmosis infection, a pneumovirus infection, a lower respiratory tract infection, an otitis media infection, a bronchiolitis infection, a viral pneumonia infection, a rhinovirus infection, an enterovirus infection, a coronavirus infection, an adenovirus infection, an influenza A or B virus infection, a herpesvirus infection, a hepatitis virus infection, an orthomyxovirus infection, a retrovirus infection, a toxoplasma infection, a cryptosporidium infection (e.g., a *Cryptosporidium parvum*) or a malaria infection.

61. The method of embodiment 60 wherein the formula 1 or 2 compound is administered intravenously and/or intraperitoneally and/or subcutaneously and/or intramuscularly and/or orally and/or topically and/or by aerosol.

62. The method of embodiment 60 or 61 wherein the formula 1 or 2 compound is administered intraperitoneally or intramuscularly or subcutaneously in a range of about 0.01 to about 30 mg/kg or orally in a range of about 0.10 to about 50 mg/kg.

63. A method of treating the common cold or related disorders selected from the group consisting of sinusitis, otitis, influenza, and infectious exacerbations of chronic obstructive pulmonary disease, or a method of treating or ameliorating one or more symptoms associated with toxoplasmosis or malaria, comprising administering to a patient in need thereof a therapeutically effective amount of (1) at least one compound of formula 1 or 2 or a compound named in embodiment 35 and (2) an antiviral or antiparasite agent specific for a virus or parasite which causes the common cold selected from the group consisting of including rhinoviruses, adenoviruses, enteroviruses, coronaviruses, respiratory syncytial viruses, influenza viruses and parainfluenza viruses.

64. A metered dose inhaler having an aerosol composition (useful for, e.g., for combating the common cold, sinusitis, otitis, influenza, a lower respiratory tract infection and infectious exacerbations of chronic obstructive pulmonary disease), the aerosol composition comprising a propellant and a compound of

claim 1.

65. A compound of formula 1 or 2 or a salt or hydrate thereof.

66. A composition comprising an effective amount of a compound of formula 1 or 2 or a salt or hydrate thereof and an excipient or a pharmaceutically acceptable carrier.

67. The composition of embodiment 66 wherein the composition comprises a unit dosage form, wherein the unit dosage form is optionally selected from a tablet, a capsule, a powder (suitable, e.g., for aerosol delivery of the compound) or a liquid.

68. The compound or composition of embodiment 65, 66 or 67 wherein the formula 1 or 2 compound is a compound or genus or group of compounds that is named or disclosed herein.

69. The compound or composition of embodiment 68 wherein the formula 1 or 2 compound comprises one, two or three -SH or =S moieties at one, two or three independently selected R₈, R₁₀ or R₁₁.

EXAMPLES

The following examples further illustrate the invention and are not to be construed as limiting the invention.

The following identifies the procedure used in a range of protocols, which establishes the efficacy of using compounds as disclosed herein. The data that establishes the efficacy is presented in the tables shown in table form.

Screening For Anti-Influenza Efficacy. Compounds known to be active against the specific viruses will be used as positive control drugs. In this assay the positive control drug is Ribavirin for both Parainfluenza and Influenza A viruses

CPE-Inhibition Assay Procedure. Mammalian cells are pregrown as monolayers in wells of 96-well tissue culture plates using suitable cell culture medium. Stock viruses are pretitered according to the method of Reed and Muench (Amer. J. Hyg. 27:493-497, 1938) and diluted in cell culture medium to yield 32- 100 CCID₅₀ (cell culture infectious dose, 50%) units per 0.1 ml. Antiviral assays are designed to test six concentrations of each compound, preferably from cytotoxic to nontoxic levels, in triplicate against the challenge virus. To each of the replicate cell cultures are added 0.1 ml of the test drug solution and 0.1 ml of virus suspension. Cell controls containing medium alone, virus-infected cell controls containing medium, and drug cytotoxicity controls containing cells, medium and each drug

concentration are run simultaneously with the test samples assayed in each experiment. The covered plates are incubated at 37°C in a humidified atmosphere containing 5% CO₂ until maximum cytopathogenic effects (CPE) are observed in the untreated virus control cultures. CPE inhibition can be determined by

5 microscopic examination or by a dye uptake (MTT) procedure.

Category 1. CPE-Inhibition (MTT) Assay (IV types A & B)

Category 2. CPE-Inhibition (Microscopic) Assay (PI-3, IV types A & B).

Protocol A1 - Category 1 - Method to quantitatively determine the degree of CPE inhibition and drug cytotoxicity. This method measures cell viability and is

10 based on the reduction of the tetrazolium salt,

3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) by mitochondrial enzymes of viable host cells to MTT formazan. (T. Mosmann, J.

Immunol. Methods. 65:55,1983). Test and control cell cultures are treated with

MTT followed by SDS to dissolve the crystals of MTT formazan. The antiviral

15 assays are set up by the CPE-inhibition procedure described above except that two additional controls are included: (1) reagent control-culture medium only (no cells); and (2) drug colorimetric controls-drug + medium (no cells). When CPE in

the untreated virus control wells reach 100%, the cultures are treated with MTT and SDS. The blue color of the MTT formazan is measured spectrophotometrically. The

20 optical density (OD) value of each culture is a function of the amount of formazan produced which is proportional to the number of viable cells. A computer program is utilized to calculate the percent reduction of the virus-infected cultures and the % cell viability of uninfected drug control cultures, as well as other indices such as the IC₅₀ (minimum inhibitory drug conc., 50%) and the Selectivity Index (minimum
25 toxic concentration/IC₅₀).

Protocol A2 - Category 2. The cell culture wells are examined microscopically for CPE and for drug cytotoxicity. Antiviral activity is determined by calculating the degree of inhibition of virus-induced CPE in drug-treated,

virus-infected cell cultures by means of a virus rating (VR). The VR is a standard

30 weighted measurement of antiviral activity taking into account both the degree of CPE inhibition and drug cytotoxicity, and is determined by a modification of the method of Ehrlich et al. (Ann. N.Y. Acad. Sci.130:5-16,1965) as described below.

CPE are graded for each individual culture in each microtiter plate well according to

a scale of 0-4 (no CPE- 100% CPE).

The VR is calculated as 0.1 of the sum of the numerical differences between the recorded CPE grades of each test well and that of the corresponding virus control in the culture plate. Numerical differences between the scores of test wells containing a drug concentration that is partially cytotoxic (p) and their

5 corresponding virus controls are halved.

A VR of 1.0 or greater is indicative of significant antiviral activity with a high degree of reproducibility in confirmatory in vitro tests. Therefore, any compound with a VR of 1.0 or greater as active (+). Any compound with a VR of 0.5-0.9 is considered to have possible or marginal activity (+), and any compound with a VR
10 of less than 0.5 is considered to be inactive (-) in the test system.

The minimum inhibitory drug concentration which reduces the CPE by 50% (MIC_{50} , or ID_{50}) is calculated by using a regression analysis program for semi log curve fitting. A therapeutic index (TI) for each active compound for each susceptible virus is determined by dividing the minimum cytotoxic concentration of
15 the test compound by the MIC_{50} .

Protocol B - Screening for anti-picornaviral activity. Each compound is tested at 5 different concentrations, in duplicate against poliovirus type I; Rhinovirus type 2 and Rhinovirus type 14 (minor and major type group viruses). The entire assay will be performed on two separate occasions. Confluent
20 monolayers of BS-C-1 (African green monkey kidney) or HEL (human embryonic lung) cells will be infected with 0.1 plaque forming units (per cell) of the respective viruses for 1 hour, in the absence of drug, and the inoculum then replaced with fresh medium containing the drug for a further 12-24 h. Monolayers will be harvested (by freeze thawing) when the drug free controls show extensive
25 cytopathic effects in 90-100% of the cells.

Virus yield from each of the control and treated cultures will be assayed by plaque assay in the absence of drug, and results presented as % infectious yield vs. concentration of drug.

Note that by using a multiplicity of infection of only 0.1 we will be able to
30 detect effects at both early and late stages of virus replication, as the assay will cover two rounds of replication. Note also that this assay format differs from the commonly used "plaque reduction assay" in which the effect of the drug is measured directly in a plaque assay, resulting in reduced numbers of plaques. The

plaque reduction assay may not detect some active drugs, since some drugs may reduce the number of plaques without making them undetectable.

Protocol C - In-vitro testing of anti *Toxoplasma gondii* activity of Cirsiolol and

Naringin. The compounds were tested in an in vitro cell culture assay utilizing

5 human fibroblasts (HFF line) as the host cell. RH strain *Toxoplasma gondii* that has been transfected with β -galactosidase as a marker for quantitative detection of parasite number (RH Bgal), was used as the challenge organism. The compounds were dissolved, and then diluted in cell culture medium at least 100 fold for the assays. Controls containing the maximum concentration of solvent used in the
10 assay were run with each test. The active drugs were added and the monolayers were infected immediately at the beginning of each test. Extracellular *T. gondii* were removed by rinsing the monolayer, and infected host cells remained in contact with the cells for the entire test period. Each test was terminated when at least four parasite doublings could be visually identified in the control monolayers,
15 and parasite numbers were quantitated by standard colorimetric assay for β -galactosidase activity with optical density at 550 nm as the readout. The optical density in this assay has a direct and linear correlation with parasite numbers over a 5-log parasite concentration. Toxicity in the host cells was determined by inspection for cytopathic effects and visual evaluation of cell growth.

20 Protocol D1 - Anti-HIV activity in fresh human cells - Assay in fresh human

T-lymphocytes. Fresh human peripheral blood lymphocytes (PBL) are isolated from donors, seronegative for HIV and HBV. Leukophoresed blood is diluted 1:1 with Dulbeccos phosphate buffered saline (PBS), layered over 14ml of FicollHypaque density gradient in a 50 ml centrifuge tube. Tubes are then centrifuged for 30
25 minutes at 600 x g. Banded PBL's are gently aspirated from the resulting interface and subsequently washed 2X with PBS by low speed centrifugation. After final wash, cells are enumerated by trypan blue exclusion and resuspended at about 1×10^7 /mL in RPMI 1640 with 15% Fetal Bovine Serum (FBS), 2 mM L-glutamine, 4 μ g/ml PHA-P and allowed to incubate for 48 to 72 hours at 37°C. After incubation,
30 the PBLs are centrifuged and reset in RPMI 1640 with 15% FBS, 2 mM L-glutamine, 100 U/mL penicillin, 100 μ g/mL streptomycin, 10 μ g/mL gentamycin and 20 U/mL recombinant human IL-2. PBL's are maintained in this medium at a concentration of $1-2 \times 10^6$ /mL with bi-weekly medium changes, until used in assay protocol.

For the PBL assay, PHA-P stimulated cells from at least two normal donors are pooled, set in fresh medium at 2×10^6 /ml and plated in the interior wells of a 96 well round bottom microplate at 50 μ L/well. Test drug dilutions are prepared at a 2X concentration in microtiter tubes and 100 μ L of each concentration is placed in appropriate wells in a standard format. 50 μ L of a predetermined dilution of virus stock is placed in each test well. Wells with cells and virus alone are used for virus control. Separate plates are identically set without virus for drug cytotoxicity studies using an XTT assay system.

In the standard PBL assay (MOI: 0.2), the assay was ended on day 7 following collection of cell free supernatant samples for reverse transcriptase activity assay. Tritiated thymidine triphosphate (NEN)(TTP) was resuspended in distilled H₂O at 5 Ci/mL. Poly rA and oligo dT were prepared as a stock solution which was kept at -20°C. The RT reaction buffer was prepared fresh on a daily basis and consists of 125 μ L of 1M EGTA, 125 μ L dH₂O, 110 μ L 10% SDS, 50 μ L 1M Tris (pH 7.4), 50 μ L M DTT and 40 μ L 1M MgCl₂. These three solutions were mixed together in a ratio of 2 parts TTP, 1 part poly rA: oligo dT and one part reaction buffer. Ten microliters of this reaction mixture was placed in a round bottomed microtiter plate and 15 μ L of virus containing supernatant was added and mixed. The plate was incubated at 37°C in a waterbath with a solid support to prevent submersion of the plate and incubated for 60 minutes.

Following reaction the reaction volume was spotted onto pieces of DE81 paper, washed 5 times for 5 minutes each in a 5% sodium phosphate buffer, 2 times for 1 minute each in distilled water, 2 times for 1 minute each in 70% ethanol and then dried. OptifluorO was added to each sample and incorporated radioactivity was quantitated utilizing a Wallac 1450 Microbetaplug liquid scintillation counter. Toxicity plates are stained with XTT as described above.

Protocol D2 - Assay in fresh human monocyte-macrophages. For isolation of adherent cells, 3×10^6 non-PHA stimulated peripheral blood cells are resuspended in Hanks buffered saline (with calcium and magnesium) supplemented with 10% human AB serum. The cells are placed in a 96-well microtiter plate at 37°C for 2 hours. Non-adherent cells are removed by vigorously washing six times. The adherent cells are cultured for 7 days in RPMI 1640 tissue culture medium with 15% fetal bovine serum. The cultures are carefully monitored for confluency during

this incubation period. Infection of the cells is performed with monocytotropic HIV-1 isolates. High titer pools of each of these viruses are harvested from infected cultures of peripheral blood adherent cells and frozen in 1.0 ml aliquots at -80°C. Monocytemacrophage monolayers are infected at a multiplicity of infection ("MOI") of 0.1. Compounds to be evaluated in the monocyte macrophage assay are added to the monolayer shortly before infection in order to maximize the potential for identifying active compounds.

At 2 days post-infection, the medium is decanted and the cultures washed twice with complete medium in order to remove excess virus. Fresh medium alone or medium containing the appropriate concentration of drug is added and incubation continued for an additional five days. XTT staining for cytotoxicity and HIV p24 ELISA assays for production of p24 core antigen are performed on Day 7 post infection. This is performed according the ELISA kit assay manufacturers recommendations. Control curves are generated in each assay to accurately quantitate the amount of capsid protein in each sample. Data is obtained by spectrophotometric analysis at 450 nm using a Molecular Devices Vmax plate reader. P24 concentrations are calculated from the optical density values by use of the Molecular Device software package Soft Max.

The table below shows results obtained from various assays. For naringin tested against HIV Ba-L, the compound was solubilised in 30% or 95% ethanol as indicated. Most of the values were based on average values that were obtained from duplicate or triplicate assay wells.

Compound	Parasite or Virus	Cell	Protocol	IC ₅₀ (μM)	TC ₅₀ (μM)	TI
7,8-Benzoflavone	HIV Ba-L	macrophage	D2	>200	>200	--
3-(4'-Bromophenyl) coumarin	parainfluenza HA-1		A2	6.3	100	16
Cirsiliol	Influenza A	MDCK	A2	>200	<6.3	--
Cirsiliol	parainfluenza HA-1	Hep2	A2	7.8	12.5	1.6
Cirsiliol	rhinovirus 14		B	~3	--	--
Cirsiliol	rhinovirus 14		B	~3	--	--
Cirsiliol	rhinovirus 14		B	~3	--	--
Cirsiliol	rhinovirus 14		B	~3	--	--
Cirsiliol	<i>T. gondii</i> RH	HFF	C	~2	--	--
Flavone	HIV ROJO	PBMC	D1	86.6	172.8	2.0
Gossypetin	HIV ROJO	PBMC	D1	1.6	8.3	5.2
Gossypetin	HIV ROJO	PBMC	D1	1.6	2.8	1.8
Gossypetin	HIV Merck	PBMC	D1	1.3	2.8	2.1

		52-52					
	Gossypetin	HIV Merck	PBMC	D1	0.9	2.8	3.0
		144-44					
5	Gossypetin	HIV Merck	PBMC	D1	0.8	2.8	3.4
		1022-48					
	Gossypetin	HIV Merck	PBMC	D1	0.8	2.8	3.6
		1002-60					
	Gossypetin	HIV Merck	PBMC	D1	2.5	2.8	1.1
		1026-60					
10	Gossypetin	HIV Merck	PBMC	D1	1.0	2.8	2.9
		1064-52					
	Gossypetin	HIV clade A	PBMC	D1	0.8	2.8	3.7
		UG/93/037					
15	Gossypetin	HIV clade B	PBMC	D1	1.4	2.8	2.0
		BR/92/014					
	Gossypetin	HIV clade E	PBMC	D1	0.9	2.8	3.2
		THA/93/073					
	Gossypetin	HIV clade F	PBMC	D1	3.1	2.8	--
		BR/92/021					
20	Gossypetin	HIV Ba-L	macrophage	D2	86.2	>100	>1.2
	Gossypetin	rhinovirus 14		B	~80	--	--
	Gossypetin	rhinovirus 14		B	>100	--	--
	Gossypetin	rhinovirus 14		B	~70	--	--
	Gossypetin	rhinovirus 14		B	~70	--	--
25	Hesperetin	HIV ROJO	PBMC	D1	134.4	190.1	1.4
	Hydroxyflavone	HIV Ba-L	macrophage	D2	63.8	>200	>3.1
	6-Hydroxyflavone	HIV ROJO	PBMC	D1	41.8	53.9	1.3
	Naringin	parainfluenza	Hep2	A2	25.0	100.0	4.0
		HA-1					
30	Naringin (35% EtOH)	HIV Ba-L	macrophage	D2	86.2	>100	>1.2
	Naringin (95% EtOH)	HIV Ba-L	macrophage	D2	>100	>100	--
	Naringin	<i>T. gondii</i> RH	HFF	C	>100	--	--
	Tangeretin	HIV ROJO	PBMC	D1	19.1	26.2	1.4
	Tangeretin	HIV ROJO	PBMC	D1	40.3	75.9	1.9
35	Tangeretin	HIV Merck	PBMC	D1	18.2	26.2	1.4
		52-52					
	Tangeretin	HIV Merck	PBMC	D1	14.7	26.2	1.8
		144-44					
40	Tangeretin	HIV Merck	PBMC	D1	9.7	26.2	2.7
		1002-60					
	Tangeretin	HIV Merck	PBMC	D1	20.8	26.2	1.3
		1022-48					
	Tangeretin	HIV Merck	PBMC	D1	19.8	26.2	1.3
		1026-60					
45	Tangeretin	HIV Merck	PBMC	D1	15.0	26.2	1.8
		1064-52					
	Tangeretin	HIV clade A	PBMC	D1	19.4	26.2	1.4
		UG/93/037					
	Tangeretin	HIV clade B	PBMC	D1	12.3	26.2	2.1
50		BR/92/014					
	Tangeretin	HIV clade E	PBMC	D1	15.3	26.2	1.7
		THA/93/073					

	Tangeretin	HIV clade F BR/92/021	PBMC	D1	15.7	26.2	1.7
	Tangeretin	HIV Ba-L	macrophage	D2	>100	>100	--
	Tangeretin	rhinovirus 14		B	~70	--	--
5	Tangeretin	rhinovirus 14		B	~20	--	--
	Tangeretin	rhinovirus 14		B	~60	--	--

HCV in vitro assays. No well-accepted model exists for HCV and new

10 compounds for use in the treatment of HCV are frequently tested for activity against bovine viral diarrhea virus (BVDV), a virus which is related to HCV.

A representative compound according to the present invention, naringin (i.e., 7-neohesperidoside, 5, 4' dihydroxyflavanone) was tested for anti-BVDV activity in MDBK cells. As a comparison, similar tests were conducted using
15 ribavirin. The results of these tests are shown in Tables A and B below. As can be seen from Tables A and B, in the case of the use of naringin (according to the present invention), the ID₅₀ was found to be 631 μ M and the therapeutic index was found to be 3.17. For ribavirin, the ID₅₀ was 1.24 μ M and the therapeutic index was 8.05. No cytotoxicity was observed with naringin at any concentration, the highest
20 concentration tested being 2000 μ M.

Table A
Effects of Naringin Upon Plaque Formation Produced by
Bovine Viral Diarrhea Virus in MDBK Cultures

Effect of Naringin on the Infectivity of the Virus in MBRK Cultures						
25		naringin conc. μg/mL	Number of plaques			% Reduction
			Test 1	Test 2	Test 3	
30	#9	2000.00	4	3	3	95.11
	#8	1500.00	8	11	8	86.82
	#7	1000.00	22	25	14	70.22
	#6	500.00	32	45	42	41.92
	#5	250.00	50	58	52	21.91
	#4	125.00	52	65	61	13.12
	#3	62.50	57	65	57	12.64
35	#2	31.25	65	75	60	2.39
	#1	0.00	68	68	68	0

ID₅₀: 631.39 Tindx: 3.16 MTC: > 2000

Control is an average of six wells (values ranged from 60 - 74)

Solvent: EtOH. Drug particles were observed at 2000 - 500 μ g/mL

40 Abbreviations:

MTC = minimum cytotoxic drug concentration

Tindx = therapeutic index

Table B

Effects of Ribavirin Upon Plaque Formation Produced by
Bovine Viral Diarrhea Virus in MDBK Cultures

5		ribavirin conc. μg/mL	Number of Plaques			
			Test 1	Test 2	Test 3	% Reduction
	#5	10.000	0	0	0	100.00*
	#4	3.200	4	4	5	93.65
	#3	1.000	36	42	47	38.99
10	#2	0.320	55	62	59	14.10
	#1	0.000	68	68	68	

* - Partial toxicity to the cells was observed with no toxicity at lower concentrations

ID₅₀: 1.24 Tindx: 8.05 MTC: > 10

Control is an average of six wells (values ranged from 60 - 74)

15 Comment: Positive control drug. Drug was soluble in medium.

Human HCV clinical trial. A human patient suffering from hepatitis C virus was treated according to the following regimen: initial dosing beginning on Day 0 (see Table C), three times daily, the patient ingested 4 g of naringin orally, and
20 then drank hot tea; in later days, the patient ingested, three times daily, 4 g of naringin mixed in hot tea. This patient also suffered from HIV infection.

The tables below, labeled part 1 through part 4, show data from this patients' bloodwork on Day 0 (when treatment according to this invention was initiated), Day 3 (3 days after Day 0), Day 6 (6 days after Day 0) and Day 9 (9 days
25 after Day 0). In addition, the tables include data from this patients' bloodwork 72 days before Day 0 ("Day -72").

PART 1	Ref. Ranges	Day -72	Day 0	Day 3	Day 6
Glucose	65-110 mg/dL	125	76	98	93
Creatinine	0.5-1.2 mg/dL		0.5	0.5	0.5
Bun/Creatinine Ratio	10 - 28	22			
SGOT	1-45 u/L	98	83	62	38
SGPT	1-45 u/L		112	102	62
WBC	$4 - 11 \times 10^3/\text{mm}^3$	3.4	3.2	3.3	3.4
RBC	$3.9 - 5.1 \times 10^6/\text{mm}^3$	4.8	4.7	4.71	4.6
Hemoglobin	13.0-17.0 g/dL	14.2	14	13.9	13.7
Hematocrit	36-46 %	41.6	41.7	40.5	40.1
MCV	82-97 cubic mic.	87	88	86	88
MCH	27-34 picograms	30	30	30	30
MCHC	32-36 %	34	34	34	34
Platelet Count	$150-400 \times 10^3/\text{mm}^3$	104	96	104	112
Metamyelocytes			0		
Lymphocytes	15-50 %	35	29	25	28

PART 2	Ref. Ranges	Day -72	Day 0	Day 3	Day 6
Bands	0-5 %	0	0		
Monocytes	0-10 %	8	5	10	6
Eosinophils	0-5 %	2	1	0	1
Basophils	0-5%	1	0	1	1
Specific Gravity	1.005-1.035			1.024	1.017
Color				Yellow	Dark Yellow
Appearance				Clear	Clear
pH	4.5-7.5			5	6
Glucose, Urine	Negative			Negative	Negative
Protein, Urine	Negative			Negative	Negative
Acetone, Urine	Negative			Negative	Negative
Occult Blood	Negative			Negative	Negative
Bilirubin	Negative			Negative	Negative
Leukocyte esterase	Negative			Negative	Negative
Nitrite	Negative			Negative	Negative

PART 3	Ref. Ranges	Day -72	Day 0	Day 3	Day 6	Day 9
Total Lymphs (% of WBC)	20-50 %		29	25	28	
Direct Lymphocyte Count	1100-3000 cells/mm ³		928	825	952	
Total T (CD3)	51-87 %		86	86	85	
Total T (Absolute #)	510-3240 #/μL		798	710	809	
Helper T (CD4)	31-59 %	25	34	22	23	
Helper T (Absolute #)	537-1571 #/μL	280	316	182	219	
Suppressor T (CD8)	13-33 %	60	58	60	59	
Suppressor T (Abs. #)	235-753 #/μL	673	538	495	562	
Helper/Suppressor	1.2-3.8	0.4	0.6	0.4	0.4	
%CD19 (Earliest B Cell)	5-25%		9	7	9	
Absolute CD19	75-700/mm ³		84	58	86	
% Dual CD56/CD16	5-30 %		3	5	4	
Absolute NK cells	30-3000/mm ³		28	41	38	
Hepatitis C RNA ultraquant	<200 copies/mL		2,871,300	1,500,900	340,540	78,592
Hepatitis C by PCR log 10			6.5	6.2	5.5	4.9

PART 4	Ref. Ranges	Day -72	Day 0	Day 3	Day 6
IgG Serum	800-1800 mg/dL		1960	2290	2050
IgA Serum	90-450 mg/dL		72.5	77.1	83.6
IgM Serum	60-280 mg/dL		211	206	225
Interferon Gamma			0		
Interleukin-2	<30 pg/mL		<30		
Interleukin-4			<30		
IL-10					
Neutrophils	50-70 FL	55	64	64	64

The patient's hepatitis C PCR ultraquant, SGOT and SGPT values are plotted in the Figure. As can be seen from Table C and the Figure, administration of naringin in accordance with the present invention provided drastic reduction in the patient's hepatitis C PCR values, as well as the patient's SGOT and SGPT values. These results would have been completely unexpected to those of skill in the art in view of contemporary knowledge.

Inhibition of rhinovirus release from infected cells. Cirsiliol was tested for its effect on rhinovirus infected cells by infecting cells with 20 PFU of rhinovirus 2, followed by addition of cirsiliol at 1 hour post infection. At time up to 10 hours post-infection, intracellular and extracellular virus was measured by plaque assay. Cirsiliol-treated cells generated lower levels of infectious intracellular and extracellular virions by about 5 to 50 fold compared to untreated control cells.



Inhibition of parasite levels *in vivo*. Mice (C57BL/6) were infected with 20 toxoplasma cysts and then treated with cirsiliol or control vehicle (0.1% DMSO). After the treatment, the level of toxoplasma cysts in the brain was reduced (about 1.5-2 fold) by the cirsiliol treatment compared to the control. Also, all 8 cirsiliol treated mice survived toxoplasmosis infection, while over the 21-day post infection follow up period, 4 of 8 control (DMSO vehicle treated) mice died by 15 days post infection.

The invention disclosed herein is not to be limited in scope by the specific described embodiments, since these embodiments are intended as illustrations of aspects of the invention. Any equivalent embodiments are intended to be within the scope of this invention. Indeed, various modifications of the invention in addition to
5 those shown and described herein will become apparent to those skilled in the art from the description. Such modifications are also intended to fall within the scope of the disclosure and the appended claims.

CLAIMS

What is claimed is:

1. A method comprising administering to a subject having a virus or a
5 parasite infection an effective amount of a composition comprising an acceptable
excipient and one or more compounds of formula 1 or 2




- 10 wherein a double or a single bond is present at the dotted line and, when a
double bond is present, (i) the optionally substituted phenyl ring at the 2- or 3-
position is present and the R₈ that is bonded to that position is absent, and (ii) one
R₈ at the adjacent 2- or 3-position is absent;

X₁ is -O- or -C(R₈)₂-;

- 15 X₂ is -C(O)- or -C(R₁₁)₂-;

each R₈ independently is -H, -OH, -SH, halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy,
glucuronide, a moiety that can hydrolyze to hydroxyl or thiol, a protecting group, a
C₁₋₂₅ fatty acid, the residue of a formula 1 or 2 compound where a hydrogen atom
is removed to form the formula 1 or 2 compound radical, -CH₂CH=C(CH₃)₂,

- 20 glucoside, a group having structure (B) or (C),



or, either R^8 and R^{10} at the 7 and 8 positions or both R^8 at the 5 and 6 positions together comprise a 6-membered aromatic ring and the remaining R^8 are independently selected from the substituents defined above

5 or, two R_8 bonded to the same carbon atom are =O or =S;

R_{10} is -OH, -SH, C_{1-6} alkyl, C_{1-6} alkoxy, a moiety that can hydrolyze to hydroxyl or thiol, a protecting group, neohesperidoside, apioglucoside, rutinose, glucoside, galactoside, rhamnoside, arabinoside, or a stereoisomer, hydrate, analog, derivative or metabolite of any of these moieties, any of which are
 10 optionally independently substituted at one or more hydrogen atoms with -OH, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, phenyl, glucuronide or a C_{1-25} fatty acid or R_{10} is -H, -OH or halogen;

each R_{11} independently is -H, -OH, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, glucuronide, a C_{1-25} fatty acid, or both R_{11} together are =O or =S; and

15 the salts, stereoisomers, positional isomers, metabolites, tautomers, ionized forms and solvates thereof.

2. The method of claim 1 wherein the virus or parasite infection is a virus infection selected from the group consisting of a respiratory syncytial virus
 20 infection, a picornavirus genus virus infection, a paramyxoviridae family virus infection, an orthomyxovirus infection, an influenza virus infection, a parainfluenza virus infection, a retrovirus infection, a hepatitis virus infection, a rhinovirus infection, a pneumovirus infection, a herpesvirus infection, an enterovirus infection or a coronavirus infection.

25

3. The method of claim 2 wherein the one or more compounds of formula 1 or 2 is cirsiol or a derivative that can convert to cirsiol or a metabolite of cirsiol.

4. The method of claim 1 wherein the infection is a parasite infection selected from the group consisting of a toxoplasmosis parasite infection, a trypanosome parasite infection and a plasmodium parasite infection.

5. The method of claim 4 wherein the virus or parasite infection is toxoplasmosis or malaria.

6. The method of claim 1 wherein the formula 1 or 2 compound is acacetin, apigenin, apiin, baicalein, baicalein trimethyl ether, 5,6-benzoflavone,

7,8-benzoflavone, 8-carboxy-3-methylflavone, dihydrorobinetin, 3,7-dihydroxy-3',4'-dimethoxyflavone, 3,5-dihydroxyflavone, 3,6-dihydroxyflavone, 3,7-dihydroxyflavone, 3,2'-dihydroxyflavone, 3,3'-dihydroxyflavone, 5,7-dihydroxyflavone, 5,2'-dihydroxyflavone, 5,3'-dihydroxyflavone, 5,4'-dihydroxyflavone, 6,7-dihydroxyflavone, 6,2'-dihydroxyflavone, 6,3'-dihydroxyflavone, 6,4'-dihydroxyflavone, 7,8-dihydroxyflavone, 7,2'-dihydroxyflavone, 7,3'-dihydroxyflavone, 7,4'-dihydroxyflavone, 2',3'-dihydroxyflavone, 2',4'-dihydroxyflavone, 3',4'-dihydroxyflavone, 5',6'-dihydroxy-7-methoxyflavone, 5',4'-dihydroxy-7-methoxyflavone, 3',4'-dihydroxy- α -naphthoflavone, 3',4'-dihydroxy- β -naphthoflavone, 5',8'-dihydroxy-3,7,3',4'-tetramethoxyflavone, 3,7'-dihydroxy-3,4,5'-trimethoxyflavone, 5,3'-dihydroxy-6,7,4'-trimethoxyflavone, 3,5'-dimethoxyflavone, 3,6'-dimethoxyflavone, 3,7'-dimethoxyflavone, 3,2'-dimethoxyflavone, 3,3'-dimethoxyflavone, 3,4'-dimethoxyflavone, 5,7'-dimethoxyflavone, 5,2'-dimethoxyflavone, 5,3'-dimethoxyflavone, 5,4'-dimethoxyflavone, 6,7'-dimethoxyflavone, 6,2'-dimethoxyflavone, 6,3'-dimethoxyflavone, 6,4'-dimethoxyflavone, 7,8'-dimethoxyflavone, 7,2'-dimethoxyflavone, 7,3'-dimethoxyflavone, 7,4'-dimethoxyflavone, 2,3'-dimethoxyflavone, 2,4'-dimethoxyflavone, 3,4'-dimethoxyflavone, 3-hydroxy-3,4'-dimethoxyflavone, 3,4'-dimethoxy- α -naphthoflavone, 3,4'-dimethoxy- β -naphthoflavone, 6,7'-dimethoxy-5,3',4'-trihydroxyflavone, 3,4'-dimethoxy-5,7',3'-trihydroxyflavone, diosmetin, diosmin, eupatorin-5-methyl ether, fisetin, flavone, fortunellin, galangin, gardenin A, geraldol, gossypetin, gossypin, 5,6,7,3',4',5'-hexamethoxyflavone, 6-hydroxyapigenin, 3-hydroxy-6,4'-dimethoxyflavone, 5-hydroxy-7,4'-dimethoxy-6,8-dimethylflavone, 3-

- hydroxyflavone, 5-hydroxyflavone, 6-hydroxyflavone, 7-hydroxyflavone,
2'-hydroxyflavone, 3'-hydroxyflavone, 4'-hydroxyflavone,
3-hydroxy-5-methoxyflavone, 3-hydroxy-6-methoxyflavone,
3,4'-dihydroxy-6-methoxyflavone, 3-hydroxy-7-methoxyflavone,
5 3-hydroxy-2'-methoxyflavone, 3-hydroxy-3'-methoxyflavone,
6'-hydroxy-7-methoxyflavone, 6'-hydroxy-2'-methoxyflavone,
6'-hydroxy-3'-methoxyflavone, 6'-hydroxy-4'-methoxyflavone,
7'-hydroxy-2'-methoxyflavone, 7'-hydroxy-3'-methoxyflavone,
7'-hydroxy-4'-methoxyflavone, 5'-hydroxy-7-methoxyflavone,
10 4'-hydroxy-5-methoxyflavone, 4'-hydroxy-6-methoxyflavone,
2'-hydroxy- α -naphthoflavone, 2'-hydroxy- β -naphthoflavone,
4'-hydroxy- α -naphthoflavone, 4'-hydroxy- β -naphthoflavone, 5-hydroxy-3,3',4',7-
tetramethoxyflavone, 3'-hydroxy-5,6,7,4'-tetramethoxyflavone, isoquercitrin,
isorhamnetin, isorhamnetin-3-glucoside, isorhamnetin-3-rutinoside, kaempferol,
15 kaempferol-3,7,4'-trimethyl ether, karanjin, luteolin, lutolin-4'-glucoside,
luteolin-7-glucoside, 4'-methoxy-5,6-benzoflavone, 3-methoxyflavone,
5-methoxyflavone, 6'-methoxyflavone, 7-methoxyflavone, 2'-methoxyflavone,
3'-methoxyflavone, 4'-methoxyflavone, 5-methoxyflavone, 3-hydroxy-
5-methoxyflavone, 6-methoxyflavone, 3-hydroxy-6-methoxyflavone,
20 4'-methoxyflavone, 3-hydroxy-7-methoxyflavone, 6-methoxyluteolin,
2'-methoxy- α -naphthoflavone, 2'-methoxy- β -naphthoflavone,
4'-methoxy- α -naphthoflavone, 4'-methoxy- β -naphthoflavone, 6-methylflavone,
8-methylflavone, 6-methyl-4'-methoxyflavone, 8-methyl-4'-methoxyflavone, morin
dihydrate, myricetin, myricetin-3-rhamnoside, naringin, naringenin, neodiosmin,
25 3,7,3',4',5'-pentamethoxyflavone, 3,6,7',3',4'-pentamethoxyflavone,
3,7,3',4',5'-pentahydroxyflavone, 5,6,7,3',4'-pentamethoxyflavone,
5,7,3',4',5'-pentamethoxyflavone, quercetagenin, quercitrin, 3,5,7,3',4'-
pentamethoxyflavone, 3,7,3',4'-tetramethoxyflavone, rutin trihydrate, 5,6,7,4'-
tetramethoxyflavone, spiraeoside, tangeretin,
30 3,5,7,4'-tetrahydroxy-3',5'-dimethoxyflavone,
3,5,3',4'-tetrahydroxy-7-methoxyflavone, 7,8,3',4'-tetrahydroxyflavone,
5,7,3',4'-tetramethoxyflavone, 7,8,3',4'-tetramethoxyflavone,
3,6,4'-trihydroxyflavone, 3,7,4'-trihydroxyflavone, 3,3',4'-trihydroxyflavone,
5,7,8-trihydroxyflavone, 5,7,2'-trihydroxyflavone,

5,3',4'-tetrahydroxy-3',5'-dimethoxyflavone, 6,3',4'-trihydroxyflavone,
7,8,2'-trihydroxyflavone, 7,8,3'-trihydroxyflavone, 7,8,4'-trihydroxyflavone,
7,3',4'-trihydroxyflavone, 3,5,7-trihydroxy-3',4',5'-trimethoxyflavone,
5,7,4'-trihydroxyflavone, 3,5,7-trimethoxyflavone, vitexin-2'-O-rhamnoside, 2-(3,4-
5 dibenzyloxy)-4,5,6-trimethoxyacetophenone, 3',4'-dibenzyloxy-2-hydroxy-4,5,6-
trimethoxydibenzoylmethane, 3',4'-dibenzyloxy-5,6,7-trimethoxyflavone,
3',4'-dihydroxy-5,6,7-trimethoxyflavone, 3',4'-diacetoxy-5,6,7-trimethoxyflavone,
3-(4'-bromophenyl)-6-methoxycoumarin, 3-(4'-bromophenyl)-7-methoxy-4-methyl
coumarin, 3-(4'-bromophenyl)-7-methoxy-4-phenyl coumarin, 3-(4'-bromophenyl)
10 coumarin, 3-(4'-bromophenyl)-6,8-dichloro-4-methyl coumarin, 3-
(4'-bromophenyl)-7-hydroxy-4-methyl coumarin, 6-bromo-3-
(4'-chlorophenyl)-4-methyl coumarin, 6-bromo-4-(4'-chlorophenyl)-3-phenyl
coumarin, 6-bromo-3,4-di-(4'-chlorophenyl) coumarin, 6-bromo-3-
(2,4-dichlorophenyl)-4-methyl coumarin, 6-bromo-3,4-diphenylcoumarin,
15 6-methoxy-4-methylcoumarin, 6-methoxy-4-methyl-3-phenylcoumarin,
7-methoxy-4-methyl-3-phenyl coumarin, 6-methoxy-3-(4'-nitrophenyl) coumarin,
6-bromo-3-(4'-methoxyphenyl)-4-methyl coumarin, 3-
(4'-bromophenyl)-6-chloro-4,7-dimethyl coumarin, 3-
(4'-bromophenyl)-6-chloro-4-methyl coumarin, 6-chloro-3
20 (2-chlorophenyl)-4-methylcoumarin, 6-chloro-3-(4'-chlorophenyl)-4-methyl
coumarin, 3-(4'-methoxyphenyl)-4-methyl coumarin, 6-methyl-3-
(4-methoxyphenyl)-4-phenyl coumarin, 3-(4'-nitrophenyl) coumarin, 6-methoxy-3-
(4-methoxyphenyl)-4-methylcoumarin, 7-methoxy-3-
(4'-methoxyphenyl)-4-methylcoumarin, 7-methoxy-3-
25 (4'-methoxyphenyl)-4-phenylcoumarin, 3-(4'-methoxyphenyl)coumarin,
6-methoxy-3-phenyl coumarin, 7-methoxy-3-phenyl coumarin, 6,8-dichloro-3-
2,4-dichlorophenyl)-4-phenylcoumarin, 6,8-dichloro-3,4-diphenyl coumarin,
6,8-dichloro-3-(4'methoxyphenyl)-4-methyl coumarin, 6,8-dichloro-3-
(4'methoxyphenyl)-4-phenyl coumarin, 3-(2,4-dichlorophenyl)coumarin, 3-
30 (2,4-dichlorophenyl)-4,6-dimethyl coumarin, 3-
(2,4-dichlorophenyl)-7-ethoxycoumarin, 3-(2,4-dichlorophenyl)-7-hydroxy coumarin,
3- (2,4-dichlorophenyl)-6-hydroxy-4-methylcoumarin, 3-
(2,4-dichlorophenyl)-7-hydroxy-4-methylcoumarin, 3-
(2,4-dichlorophenyl)-6-ethoxy-4-methyl coumarin, 3-

- (2,4-dichlorophenyl)-7-ethoxy-4-methylcoumarin, 3-
 (2,4-dichlorophenyl)-7-ethoxy-4-phenylcoumarin, 3-cyano-6-methoxycoumarin,
 3-cyano-7-methoxy coumarin, 6, 8-dichloro-3
 (2,4-dichlorophenyl)-4-methylcoumarin, 3-(4'-chlorophenyl)-4-methylcoumarin,
 5 3-cyano-7-ethoxy coumarin, 3-cyano-7-hydroxycoumarin,
 3-cyano-7-hydroxy-4-methylcoumarin, 3-
 (2-chlorophenyl)-7-methoxy-4-phenylcoumarin, 3-
 (4'-chlorophenyl)-7-methoxy-4-phenyl coumarin, 3-
 (2-chlorophenyl)-4-methylcoumarin, 3-(2-chlorophenyl)-7-methoxycoumarin, 3-
 10 (4'-chlorophenyl)-7-methoxy coumarin, 3-
 (2-chlorophenyl)-7-methoxy-4-methylcoumarin, 3-
 (4'-chlorophenyl)-7-methoxy-4-methyl coumarin, 3-
 (2-chlorophenyl)-7-hydroxy-4-phenylcoumarin, 3-
 (4'-chlorophenyl)-7-hydroxy-4-phenyl coumarin, 3-(4'-chlorophenyl)-6-methoxy
 15 coumarin, 3-(4'-chlorophenyl)-7-hydroxycoumarin, 3-
 (2-chlorophenyl)-7-hydroxy-4-methylcoumarin, 3-
 (4'-chlorophenyl)-7-hydroxy-4-methyl coumarin, 3-
 (2-chlorophenyl)-7-ethoxy-4-methylcoumarin, 3-
 (2-chlorophenyl)-7-ethoxy-4-phenylcoumarin, 3-
 20 (2-chlorophenyl)-7-hydroxycoumarin, 4-(4-chlorophenyl)-3-
 (2,4-dichlorophenyl)-6-methylcoumarin, 3-(2-chlorophenyl)-4,6-dimethylcoumarin,
 3-(2-chlorophenyl)-7-ethoxycoumarin, 3-(4'-chlorophenyl)-7-ethoxycoumarin, 3-
 (2-chlorophenyl)-6,8-dichloro-4-methylcoumarin, 3-
 (4'-chlorophenyl)-6,8-dichloro-4-methyl coumarin, 4-
 25 (4'-chlorophenyl)-6,8-dichloro-3-phenyl coumarin, 6-chloro-3-
 (4'-methoxyphenyl)-4-phenyl coumarin, 6-chloro-4-methyl-3-(4'-nitrophenyl)
 coumarin, 3-(2-chlorophenyl) coumarin, 7-hydroxy-3-
 (4'-methoxyphenyl)-4-methylcoumarin, 7-hydroxy-3-(4'-methoxyphenyl)-4-phenyl
 coumarin, 6-hydroxy-4-methyl-3-phenylcoumarin, 6-ethoxy-4-methylcoumarin,
 30 6-ethoxy-4-methyl-3-phenyl coumarin, 7-hydroxy-3-(4'-methoxyphenyl) coumarin,
 6-hydroxy-3(4-methoxyphenyl)-4-methylcoumarin, 6-ethoxy-3
 (4-methoxyphenyl)-4-methylcoumarin, 7-ethoxy-3(4'-methoxyphenyl)-4-methyl
 coumarin, 7-ethoxy-3(4'-methoxyphenyl)-4-phenyl coumarin,
 4,6-dimethyl-3(4-methoxyphenyl)coumarin, 3,4-diphenyl-7-methoxy coumarin,

- 3,4-diphenyl-6-methyl coumarin, 7-ethoxy-3(4'methoxyphenyl) coumarin,
 3,4-diphenyl-7-hydroxy coumarin, 3-
 (2,4-dichlorophenyl)-7-hydroxy-4-phenylcoumarin, 3-
 (2,4-dichlorophenyl)-7-methoxycoumarin, 3-
 5 (2,4-dichlorophenyl)-6-methoxy-4-methylcoumarin, 3-
 (2,4-dichlorophenyl)-7-methoxy-4-methylcoumarin, 3-
 (2,4-dichlorophenyl)-7-methoxy-4-phenylcoumarin, 3-(2,4-dichlorophenyl)-4-methyl
 coumarin, 6-chloro-3-formyl-7-methylcoumarin,
 6-chloro-3(4'-methoxyphenyl)-4-methyl coumarin,
 10 6-chloro-3(4'-methoxyphenyl)-7-methyl-4-phenyl coumarin,
 6-chloro-4,7-dimethyl-3-(4'-methoxy phenyl) coumarin, 6-chloro-3,4-diphenyl
 coumarin, 6-chloro-3,4-diphenyl-7-methyl coumarin,
 6-chloro-3,4-di(4'-chlorophenyl)-7-methyl coumarin, 6-chloro-3
 (2,4-dichlorophenyl)-7-methyl-4-phenylcoumarin, 6-chloro-3
 15 (2,4-dichlorophenyl)-4-phenylcoumarin, 6-chloro-3-
 (2-chlorophenyl)-7-methyl-4-phenylcoumarin, 6-chloro-3
 (2-chlorophenyl)-4-phenylcoumarin, 6-chloro-4-(4'-chlorophenyl)-3-phenyl
 coumarin, 6-chloro-3,4-di-(4'-chlorophenyl) coumarin, 6-chloro-3-
 (2,4-dichlorophenyl)-4,7-dimethyl coumarin, 6-chloro-3-
 20 (2,4-dichlorophenyl)-4-methylcoumarin, 6-chloro-3-(4'-chlorophenyl)-4,7-dimethyl
 coumarin, 6-chloro-4-(4'-chlorophenyl)-3-(4'methoxy phenyl) coumarin, 6-chloro-4-
 (4'-chlorophenyl)-3-(4'methoxy phenyl)-7-methyl coumarin, 6-chloro-4-
 (4-chlorophenyl)-3-(2,4-dichlorophenyl) coumarin, 6-chloro-4-(4-chlorophenyl)-3-
 (2,4-dichlorophenyl)-7-methylcoumarin, 6-chloro-3-
 25 (2-chlorophenyl)-4,7-dimethylcoumarin, 6-chloro-3-
 (2-chlorophenyl)-4-methylcoumarin, 6-chloro-3-(4'-chlorophenyl)-4-methyl
 coumarin, 7-hydroxy-4-methyl-3-phenyl coumarin, 7-hydroxy-3-phenyl coumarin,
 6-methoxy-3-(4'-methoxyphenyl) coumarin or 7-methoxy-3-(4'-methoxyphenyl)
 coumarin.

30

7. The method of claim 6 wherein the virus or parasite infection is a virus infection selected from the group consisting of a respiratory syncytial virus infection, a paramyxoviridae family virus infection, an orthomyxovirus family virus infection, a picornavirus genus virus infection, an influenza virus infection, a

parainfluenza virus infection, a retrovirus infection, a rhinovirus infection, a pneumovirus infection, a herpesvirus infection, an enterovirus infection, a coronavirus infection a hepatitis virus infection.

5 8. The method of claim 6 wherein the virus infection is an HIV or HCV infection or a Picornavirus genus virus infection.

 9. The method of claim 6 wherein the virus or parasite infection is a parasite infection selected from the group consisting of toxoplasmosis parasites,
10 trypanosome parasite and plasmodium parasite infections.

 10. The method of claim 6 wherein the virus or parasite infection is a toxoplasmosis infection or a malaria infection.

15 11. The method of claim 1 wherein one, two or three independently selected R_8 , R_{10} or R_{11} are -SH or =S.

 12. A method of treating or preventing a common cold, a lower respiratory tract infection, a bronchiolitis infection, a pneumonia infection, influenza,
20 otitis media, sinusitis, influenza, or an infectious exacerbation of chronic obstructive pulmonary disease, or of ameliorating one or more symptoms of any of these conditions, comprising administering to a subject having a cold a composition comprising a carrier and an effective amount of the compound of claim 1.

25 13. The method of claim 12 wherein the compound of claim 1 is one or more of cirsiolol, tangeretin, gossypetin, naringenin, naringin or a derivative of any of these compounds that can convert to cirsiolol, tangeretin, gossypetin, naringenin or naringin.

30 14. The method of claim 12 wherein the subject has a common cold.

 15. The method of claim 22 wherein the subject is a human.

16. The method of claim 15 wherein the compound of claim 1 is cirsiolol or a derivative of cirsiolol that can convert to cirsiolol.

17. A method of treating or preventing a rhinovirus infection, a
5 pneumovirus infection, an orthomyxovirus family virus infection, a paramyxoviridae family virus infection, a picornavirus genus virus infection, a respiratory syncytial virus infection, an influenza virus infection, a parainfluenza virus infection, a retrovirus infection, an adenovirus infection or a hepatitis virus infection, comprising
10 administering to a subject having a cold a composition comprising a carrier and an effective amount of the compound of claim 1.

18. The method of claim 17 wherein the retrovirus infection or the hepatitis virus infection is a HIV, SIV, FIV, HBV or HCV infection.

15 19. The method of claim 17 wherein the compound of claim 1 is one or more of cirsiolol, tangeretin, gossypetin, naringenin, naringin or a derivative of any of these compounds that can convert to cirsiolol, tangeretin, gossypetin, naringenin or naringin.

20 20. The method of claim 1 wherein the infection is toxoplasmosis or malaria.

21. The method of claim 20 wherein the compound of claim 1 is one or more of cirsiolol, tangeretin, gossypetin, naringenin, naringin or a derivative of any
25 of these compounds that can convert to cirsiolol, tangeretin, gossypetin, naringenin or naringin.

22. The method of claim 1 wherein the compound of claim 1 is administered intravenously and/or intraperitoneally and/or subcutaneously and/or
30 intramuscularly and/or orally and/or topically and/or by aerosol.

23. The method of claim 22 wherein the compound of claim 1 is administered intraperitoneally or intramuscularly or subcutaneously in a range of about 0.01 to about 30 mg/kg.

24. The method of claim 22 wherein the compound of claim 1 is administered orally in a range of about 0.10 to about 50 mg/kg.

5 25. A method comprising administering to a subject having a virus or a
parasite infection an effective amount of a composition comprising an acceptable
excipient and 2-(3,4-dibenzyloxy)-4,5,6-trimethoxyacetophenone or 3',4'-
dibenzyloxy-2-hydroxy-4,5,6-trimethoxydibenzoylmethane or the salts,
stereoisomers, positional isomers, metabolites, tautomers, ionized forms or
10 solvates thereof.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 January 2001 (18.01.2001)

PCT

(10) International Publication Number
WO 01/03681 A3

(51) International Patent Classification⁷: **A61K 31/37**,
31/352, 31/353, A61P 31/12, 31/14, 31/16, 31/18, 31/20,
31/22, 33/02, 33/06, A61K 31/35

(21) International Application Number: PCT/IB00/01039

(22) International Filing Date: 7 July 2000 (07.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/142,894 8 July 1999 (08.07.1999) US
60/163,089 2 November 1999 (02.11.1999) US

(71) Applicant and

(72) Inventor: **PRENDERGAST, Patrick, T.** [IE/IE]; Bay-
bush, Straffan, County Kildare (IE).

(74) Agent: **TAUCHNER, Paul**; Vossius & Partner, Siebert-
strasse 4, D-81675 München (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AT
(utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA,

CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility
model), DK, DK (utility model), DM, DZ, EE, EE (utility
model), ES, FI, FI (utility model), GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (utility
model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,
MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT,
TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
10 May 2002

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS

(57) Abstract: The invention provides the use of flavin compounds or coumarins, as well as 2-(3',4'-dibenzoyloxy)-4,5,6-trimethoxy acetophenone or 3',4'-dibenzoyloxy-2-hydroxy-4,5,6-trimethoxy dibenzoylmethane or derivatives thereof, more particularly cirsiolol, 3',4'-diacetoxy-5,6,7-trimethoxyflavone, naringin, naringenin, tangeretin or gossypetin, in the treatment of viral (e.g. RSV, HIV, SIV, picornavirus, rhinovirus, 'para!myxoviridae or orthomyxoviridae, (para)influenza, retrovirus, hepatitis virus, pneumovirus, herpes (HSV), entero- or coronavirus) or parasitic (e.g., malaria, toxoplasmosis, trypanosoma) infections.

WO 01/03681 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 00/01039

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/37 A61K31/352 A61K31/353 A61P31/12 A61P31/14
A61P31/16 A61P31/18 A61P31/20 A61P31/22 A61P33/02
A61P33/06 A61K31/35

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EP0-Internal, BIOSIS, EMBASE, MEDLINE, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 348 509 A (TSUMURA) 3 January 1990 (1990-01-03) abstract page 5 -page 10 page 13 -page 16 ----	1,2,6-8, 17,18, 22-24
X	WO 97 47270 A (ARAD) 18 December 1997 (1997-12-18) abstract pages 7-8 formulas IX and XII page 24 compound 100 page 31 2nd Table formulas IX and XII page 32 ----- -/--	1,2,6-8, 17,18, 22-24

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

16 November 2001

Date of mailing of the international search report

12/12/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gac, G

INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/IB 00/01039

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 019 081 A (F. HOFFMANN-LAROCHE) 26 November 1980 (1980-11-26) see the whole document, especially page 5 lines 20-26, page 12 lines 22-30 and page 14 lines 32-37 ---	1-3,6,7, 12-17, 19,22-24
X	EP 0 373 986 A (FONDATION POUR L'ENCOURAGEMENT À LA RECHERCHE MÉDICALE) 20 June 1990 (1990-06-20) the whole document ---	1,2,6,8, 12,13, 15,17, 18,21-24
X	EP 0 861 662 A (COLEMAN T.) 2 September 1998 (1998-09-02) the whole document ---	1,2,12, 14,15, 17,22
X	WO 98 46238 A (MEDICHEM RESEARCH) 22 October 1998 (1998-10-22) the whole document ---	1,2,12, 14,15, 17,18, 22-24
X	WO 92 14458 A (FOCKERMAN) 3 September 1992 (1992-09-03) abstract page 1, line 11 - line 15 page 2, line 22 page 5, line 28 ---	1,2,6,7, 12-15, 17,19, 21-24
X	WO 98 42188 A (SQUIRES) 1 October 1998 (1998-10-01) page 8 -page 9 page 12 lines 2,3,9-11 page 18, line 30 page 19, line 10 - line 12 ---	1,2,6-8, 12,15, 17,18, 22-24
P,X	WO 99 44578 A (MERCK PATENT GMBH) 10 September 1999 (1999-09-10) the whole document ---	1,22-24
P,X	WO 00 32201 A (HOLLIS-EDEN PHARMACEUTICALS INC.) 8 June 2000 (2000-06-08) abstract page 6 -page 7 page 69 -page 72 page 77 -page 79 ---	1-24

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 00/01039

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 99 49862 A (THE UNIVERSITY OF MISSISSIPPI) 7 October 1999 (1999-10-07) the whole document ---	1,4-6,9, 20,22-24
P,X	WO 00 32177 A (HOLLIS-EDEN PHARMACEUTICALS) 8 June 2000 (2000-06-08) abstract page 7 claims 19,20,24-28 ---	1-24
X	DATABASE WPI Week 199750 Derwent Publications Ltd., London, GB; AN 1997-539680 XP002183224 & JP 09 227373 A (TEIJIN LTD), 2 September 1997 (1997-09-02) abstract ---	1,2,6,7, 12-15, 17,22
X	DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; STN AN: 1995:528568, XP002183216 abstract & JP 07 002826 A (SANWA KAGAKU KENKYUSHO CO) 6 January 1995 (1995-01-06) the whole document ---	1-3,6,7, 11-17, 19,21, 22,24
X	DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; STN AN : 2001:179996, XP002183217 abstract & RO 114 410 B (ROM.) 30 April 1999 (1999-04-30) the whole document ---	1,2,6,7, 12
A	---	15,17,22
X	DATABASE WPI Week 198333 Derwent Publications Ltd., London, GB; AN 1983-739004 XP002183225 & RO 75 776 A (INTR. MEDICAMENTE TERAPIA), 15 October 1982 (1982-10-15) abstract ---	1,2,6,7, 12,14, 17,22,24

	-/--	

INTERNATIONAL SEARCH REPORT

Int. .tional Application No

PCT/IB 00/01039

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PATENT ABSTRACTS OF JAPAN vol. 0, no. 0 & JP 07 277969 A (SOUYAKU GIJUTSU KENKYUSHO KK), 24 October 1995 (1995-10-24) abstract	1,2,6,7, 12,14, 17,22,23
A	---	15,19
X	DATABASE WPI Week 199108 Derwent Publications Ltd., London, GB; AN 1991-055557 XP002183226 & JP 03 007224 A (TSUMURA) abstract & PATENT ABSTRACTS OF JAPAN vol. 0, no. 0 & JP 03 007224 A (TSUMURA) abstract	1,2,6-8, 17-19, 22-24
X	---	
X	PATENT ABSTRACTS OF JAPAN vol. 0, no. 0 & JP 04 018019 A (KITASATO INST.), 22 January 1992 (1992-01-22) abstract	1,2,6,7, 12-14, 17,19, 22-24
A	& JP 04 018019 A (TSUMURA) 22 January 1992 (1992-01-22) & DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; STN AN: 1992:262514, the whole document	15
X	---	
X	PATENT ABSTRACTS OF JAPAN vol. 0, no. 0 & JP 02 101013 A (DAICEL CHEM IND.) abstract & JP 02 101013 A (DAICEL CHEM. IND.) 12 April 1990 (1990-04-12) & DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; STN AN= 1991:35977, the whole document	1,2,6,7, 17,19
X	---	
X	DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; STN AN= 1994:646288, XP002183218 abstract & JP 06 199697 A (YUNIE KK) 19 July 1994 (1994-07-19) the whole document	1,2,6,7, 12,14,17

	-/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 00/01039

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE VETU 'Online! GLINSKI Z ET AL: "The Antimicrobial Activity of Propolis. (Przeciwdrobnoustrojowe Działanie Propolisu.)" retrieved from STN Database accession no. 1987-62306 XP002183219 abstract & MED.WETER. (43, NO. 2, 74-79, 1987) 1 FIG. 71 REF. (Z46/JLC) CODEN: MDWTAG,</p>	<p>1,2,4,5, 7,9,10, 12,17, 20,22</p>
X	<p>--- DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; LEE, JI-HYUN (1) ET AL: "Antiherpetic activities of natural naringenin alone and in combinations with acyclovir and vidarabine." retrieved from STN Database accession no. PREV199900309481 XP002183220 the whole document & YAKHAK HOEJI, (FEB., 1999) VOL. 43, NO. 1, PP. 77-84.,</p>	<p>1,2,6,7, 17,19</p>
X	<p>--- DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; LEE, JI-HYUN ET AL: "Antiviral activity of some flavonoids on herpes simplex viruses" retrieved from STN Database accession no. 131:165028 XP002183221 the whole document & SAENGYAK HAKHOECHI (1999), 30(1), 34-39,</p>	<p>1,2,6,7, 17,19</p>
X	<p>--- BRINKWORTH R I ET AL: "Flavones are Inhibitors of HIV-1 Proteinase." BIOCHEM.BIOPHYS.RES.COMMUN. (188, NO. 2, 631-37, 1992) 1 FIG. 2 TAB. 21 REF. CODEN: BBRCA9 ISSN: 0006-291X, XP001031188 the whole document, especially table 2 page 634 --- -/--</p>	<p>1,2,6-8, 17-19</p>

INTERNATIONAL SEARCH REPORT

Int. Application No
PCT/IB 00/01039

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CRITCHFIELD J W ET AL: "INHIBITION OF HIV ACTIVATION IN LATENTLY INFECTED CELLS BY FLAONOID COMPOUNDS" AIDS RESEARCH HUMAN RETROVIRUSES (1996) 12 (1) P. 39-46., XP001031189 RETROVIRUS DIS BRANCH, DIV VIRAL RICKETTSIAL, NATL CENT INFECT DIS, ATLANTA GA 30333 USA the whole document	1,2,6-8, 17,18
X	PATHAK D ET AL: "Flavonoids as Medicinal Agents - Recent Advances." FITOTERAPIA (62, NO. 5, 371-89, 1991) 166 REF. CODEN: FTRPAE ISSN: 0367-326X, XP001039766 page 380, paragraph 3	1,2,6-8, 12,17,18
X	LIU K C S C ET AL: "Antimalarial Activity of Artemisia Annua Flavonoids from Whole Plants and Cell Cultures." PLANT CELL REP. (11, NO. 12, 637-40, 1992) 3 TAB. 2 FIG. 16 REF. CODEN: PCRPD8 ISSN: 0721-7714, XP001039836 page 639 left column "antimalarial activity of methoxylated flavones"	1,4-6,9, 10,20,21
X	HU, CHANG QI ET AL: "Anti-aids agents, 10. Acacetin-7-O-.beta.-D-galactopyranoside, an anti-HIV principle from Chrysanthemum morifolium and a structure-activity correlation with some related flavonoids" J. NAT. PROD. (1994), 57(1), 42-51, XP001039690 the whole document	1,2,6-8, 17,18
X	KHALID S A ET AL: "POTENTIAL ANTIMALARIAL CANDIDATES FROM AFRICAN PLANTS: AN IN VITRO APPROACH USING PLASMODIUM FALCIPARUM" J ETHNOPHARMACOL (1986) 15 (2) P. 201-209., XP001039769 DEPT PHARMACOG, FAC PHARM, UNIV KHARTOUM, KHARTOUM SUDAN Table 1 page 203 and Fig. 1 page 205	1,4,5,20
Y A	---	6,9 10

	-/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 00/01039

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KAIJ A KAMB M ET AL: "Search for New Antiviral Agents of Plant Origin." PHARM.ACTA HELV. (67, NO. 5-6, 130-47, 1992) 2 TAB. 86 REF. CODEN: PAHEAA ISSN: 0031-6865, XP001039765 pages 137 (axillarin, apigenin; page 138: chrysosplenol B and C, centaurein; page 140: fisetin, page 141: hesperidin, page 142: jacein, luteolin (+ derivative), page 143: morin, naringin, pelargo pages 145 and 147	1,2,6-8, 12,17
X	WLEKLIK, M. ET AL: "Structural basis for antiviral activity of flavonoids - naturally occurring compounds" ACTA VIROL. (ENGL. ED.) (1988), 32(6), 522-5, XP001039754 the whole document	1,2,6-8, 17,18
X	TSUCHIYA, YOSHINORI ET AL: "Antiviral activity of natural occurring flavonoids in vitro" CHEM. PHARM. BULL. (1985), 33(9), 3881-6, XP002101665 the whole document	1,2,6-8, 12,14,17
X	KUSUMOTO I T ET AL: "A COMPARATIVE STUDY ON THE INHIBITORY EFFECTS OF FLAVONOIDS AND ALKALOIDS ON REVERSE TRANSCRIPTASES OF DIFFERENT RETROVIRUSES" SHOYAKUGAKU ZASSHI (1993) 47 (3) P. 291-294., XP001039764 RES INST ORIENTAL MED, TOYAMA MED & PHARM UNIV, TOYAMA 930-01 JAPAN the whole document	1,2,6-8, 17,18
X	KUSUMOTO, INES TOMOCO ET AL: "Effects of flavonoids and alkaloids on reverse transcriptase" SHOYAKUGAKU ZASSHI (1991), 45(3), 240-54, XP000579880 the whole document	1,2,6-8, 17-19
X	WACKER A ET AL: "Antiviral activity of plant components. Part 1. Flavonoids." ARZNEIM.-FORSCH. (1978).VOL. 28, NO. 3, PP. 347-50. CODEN: ARZNAD., XP002101663 Zentr. Biol. Chem., Univ. Frankfurt, Frankfurt/Main, Ger. page 349 Table 6 and right column first paragraph	1,2,6,7, 12,17

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB 00/01039

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LIN, YUH-MEEI ET AL: "In Vitro Anti-HIV Activity of Biflavanoids Isolated from <i>Rhus succedanea</i> and <i>Garcinia multiflora</i> " J. NAT. PROD. (1997), 60(9), 884-888, XP001039752 the whole document	1,2,17, 18
X	GRAEL C F F ET AL: "Trypanocidal activity of crude extracts and compounds from <i>Lychnophora granmongolense</i> (Duarte) semir and leitao filho (vernonieae, asteraceae)." BOLL.CHIM.FARM. (138, NO. 2, LVII, FEB. 1999) 5 REF. CODEN: BCFAAI ISSN: 0006-6648, XP001039822 Univ.Sao-Paulo the whole document	1,4,6,9
X	SCHINOR E C ET AL: "Biological activity of the crude extracts and some isolated substances from <i>Moquinia kiingi</i> (DC) H. Robinson." BOLL.CHIM.FARM. (138, NO. 2, LXXIII, FEB. 1999) CODEN: BCFAAI ISSN: 0006-6648, XP001039842 Univ.Sao-Paulo the whole document	1,4,6,9
X	LOPES N P ET AL: "Flavonoids and lignans from <i>Virola surinasmensis</i> twigs and their in vitro activity against <i>Trypanosoma cruzi</i> ." PLANTA MED. (64, NO. 7, 667-69, 1998) 1 FIG. 1 TAB. 16 REF. CODEN: PLMEAA ISSN: 0032-0943, XP001039767 Univ.Sao-Paulo;Univ.Paulista-State the whole document	1,4
Y		6,9
X	MAHMOOD N ET AL: "Inhibition of HIV Infection by Flavanoids." ANTIVIRAL RES. (22, NO. 2-3, 189-99, 1993) 1 FIG. 6 TAB. 23 REF. CODEN: ARSRDR ISSN: 0166-3542, XP001039821 Univ.Naples the whole document	1,2,17, 18
Y		6-8
	--- -/--	

II INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 00/01039

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KAUL T N ET AL: "INTERACTION OF FLAVONOIDS AND VIRUSES IN-VITRO POTENTIAL ROLE IN ANTI VIRAL THERAPY." 38TH ANNUAL MEETING OF THE AMERICAN ACADEMY OF ALLERGY, MONTREAL, QUEBEC, CANADA, MARCH 6-10, 1982. J ALLERGY CLIN IMMUNOL. (1982) 69 (1 PART 2), 104., XP001039866 the whole document	1,2,17, 18
Y	---	6-8
X	BURNHAM, WELDON S. ET AL: "Synthesis and antiviral activity of 4'-hydroxy-5,6,7,8-tetramethoxyflavone" J. MED. CHEM. (1972), 15(10), 1075-6, XP001031173 the whole document	1,2, 12-14, 17,19
Y	---	6-8
X	RAZ B ET AL: "Phytochemical investigation of the African medicinal plant Ehretia amoena for the identification of trypanocidal molecules." TROP.MED.INT.HEALTH (1, NO. 6, A30-A31, 1996) CODEN: TMIHFL ISSN: 1360-2276, XP001039869 Swiss-Trop.Inst.;Univ.Lausanne the whole document	1,4
Y	---	6,9
X	ZANI C.L. ET AL: "Trypanocidal components of Pluchea quitoc L.." PHYTOTHERAPY RESEARCH, (1994) 8/6 (375-377)., XP001039757 the whole document	1,4
Y	---	6,9
A	---	3
X	GONZALEZ J ET AL: "IN VITRO ACTIVITY OF NATURAL PRODUCTS AGAINST THE TRYPOMASTIGOTE FORM OF TRYPANOSOMA CRUZI" PHYTOTHER RES (1990) 4 (1) P. 1-4., XP001039755 DEPT PRECLIN SCI, UNIV ANTOFAGASTA, ANTOFAGASTA CHILE page 3; table 4	1,4
Y	---	6,9
A	---	25
	page 2; table 3 ---	

	-/--	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB 00/01039

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE DRUGU 'Online! CASTRILLO J L ET AL: "3-Methylquercetin Is a Potent and Selective Inhibitor of Poliovirus RNA Synthesis." retrieved from STN Database accession no. 1986-48913 XP002183222 abstract & VIROLOGY (152, NO. 1, 219-27, 1986) 7 FIG. 17 REF. CODEN: VIRLAX ISSN: 0042-6822,</p>	1,2
A	<p>----- HORIE, TOKUNARU ET AL: "Syntheses of 3',4'-dihydroxy-5,6,7- and 5,7,8-trioxygenated 3',4'-dihydroxy flavones having alkoxy groups and their inhibitory activities against arachidonate 5-lipoxygenase" J. MED. CHEM. (1986), 29(11), 2256-62, XP001031172 the whole document</p>	3,25
X	<p>----- LIEN, ERIC J. ET AL: "Epstein-Barr virus DNA polymerase inhibitors from Chinese herbs: use of preliminary screening, physicochemical properties and taxonomy for new lead compounds generation" CHIN. PHARM. J. (TAIPEI) (1998), 50(4), 233-247, XP001039794 Table 1 page 235; compounds 3,4,18,22,24; Table 3 compounds 3,4,18,24,34</p>	1,2,6,7, 17
X	<p>----- RIBEIRO A ET AL: "Trypanocidal flavonoids from Trixis vauthieri." JOURNAL OF NATURAL PRODUCTS, (1997 AUG) 60 (8) 836-41., XP001039751 the whole document</p>	1,4,6,9
X	<p>----- KAUL T N ET AL: "ANTIVIRAL EFFECT OF FLAVONOIDS ON HUMAN VIRUSES" JOURNAL OF MEDICAL VIROLOGY, NEW YORK, NY, US, vol. 15, no. 1, January 1985 (1985-01), pages 71-80, XP000990920</p>	1,2,17, 18
Y	<p>the whole document</p>	6-8
	----- -/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 00/01039

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FORMICA J V ET AL: "REVIEW OF THE BIOLOGY OF QUERCETIN AND RELATED BIOFLAVONOIDS" FOOD AND CHEMICAL TOXICOLOGY, XX, XX, vol. 33, no. 12, 1995, pages 1061-1080, XP000886722 ISSN: 0278-6915	1,2,12, 17
Y	page 1065, right-hand column page 1066, right-hand column ---	6-8
X	FESSEN M R ET AL: "INHIBITION OF HIV-1 INTEGRASE BY FLAVONES, CAFFEIC ACID PHENETHYL ESTER (CAPE) AND RELATED COMPOUNDS" BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 48, no. 3, 1994, pages 595-608, XP000911085 ISSN: 0006-2952 the whole document ---	1,2,6-8, 17-19
X	ALVES, C. N. ET AL: "A quantum chemical and statistical study of flavonoid compounds with anti-HIV activity" THEOCHEM (1999), 491, 123-131, XP001039687 the whole document ---	1,2,6-8, 17,19
X	VLIETINCK A J ET AL: "PLANT-DERIVED LEADING COMPOUNDS FOR CHEMOTHERAPY OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION" PLANTA MEDICA, THIEME, STUTTGART, DE, vol. 64, no. 2, March 1998 (1998-03), pages 97-109, XP001028147 ISSN: 0032-0943 pages 100,101, 103 (compounds 28-30,32-40) ---	1,2,6-8, 17-19
X	DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; STN AN: 1990:400163, XP002183223 abstract & ONO ET AL.: "Differential inhibitory effects of various flavonoids on the activities of reverse transcriptase and cellular DNA and RNA polymerases" EUR. J. BIOCHEM., vol. 190, no. 3, 1990, pages 469-476, the whole document --- -/--	1,2,6,7, 17,18

INTERNATIONAL SEARCH REPORT

Int. Application No

PCT/IB 00/01039

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>EGAN D ET AL: "The Pharmacology, Metabolism, Analysis and Applications of Coumarin and Coumarin-Related Compounds." DRUG METAB.REV. (22, NO. 5, 503-29, 1990) 4 FIG. 2 TAB. 89 REF. CODEN: DMTRAR ISSN: 0360-2532, XP001039763 page 513, last paragraph -----</p>	6,9

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-24 relate to an extremely large number of possible compounds and disorders : formulas are too broad and may include an unlimited and undefined number of possible variables, permutations or options, and the expressions "derivative that can convert to...", "metabolite", "a(n) ...virus" or "a parasite" are so vague that they are lacking clarity and conciseness within the meaning of Article 6 PCT. This arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear, well supported and concise, namely on :

* Compounds : cirsiolol, tangeretin, gossypetin, naringenin and naringin (claim 13) and completed by flavone and hesperetin (since they were exemplified) and the two compounds of claim 25.

* Diseases: common cold, RSV, HSV, HIV, SIV, HBV, HCV (hepatitis), influenza, rhinovirus, toxoplasmosis, Trypanosoma, and malaria (Plasmodium).

Other diseases caused by virus of other types mentioned for example in claims 12 and 17 have only been searched partially (no deep neither complete search was performed on all potential specific viruses possibly included in general viral families).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 00/01039

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 348509	A	03-01-1990	JP 1835115 C	11-04-1994
			JP 2069415 A	08-03-1990
			JP 5044925 B	07-07-1993
			JP 1153646 A	15-06-1989
			JP 1784069 C	31-08-1993
			JP 4070287 B	10-11-1992
			JP 1163120 A	27-06-1989
			JP 1836443 C	11-04-1994
			JP 5051565 B	03-08-1993
			JP 1163121 A	27-06-1989
			JP 1836444 C	11-04-1994
			JP 5051566 B	03-08-1993
			JP 1163122 A	27-06-1989
			JP 1836445 C	11-04-1994
			JP 5051567 B	03-08-1993
			AT 87204 T	15-04-1993
			DE 3879688 D1	29-04-1993
			DE 3879688 T2	01-07-1993
			EP 0348509 A1	03-01-1990
			WO 8905141 A1	15-06-1989
			KR 9203577 B1	04-05-1992
WO 9747270	A	18-12-1997	AU 737322 B2	16-08-2001
			AU 3046197 A	07-01-1998
			CA 2258560 A1	18-12-1997
			EP 0914130 A2	12-05-1999
			HU 0000734 A2	28-04-2001
			WO 9747270 A2	18-12-1997
			JP 2000505479 T	09-05-2000
			NO 985864 A	12-02-1999
EP 19081	A	26-11-1980	AU 538214 B2	02-08-1984
			AU 5715780 A	16-10-1980
			BR 8002191 A	25-11-1980
			CU 35257 A2	28-03-1982
			DE 3069488 D1	29-11-1984
			DK 152980 A	15-10-1980
			EP 0019081 A1	26-11-1980
			FI 801050 A	11-10-1980
			GR 67731 A1	16-09-1981
			IE 49670 B1	13-11-1985
			IL 59770 A	31-07-1984
			JP 1018049 B	03-04-1989
			JP 1530699 C	15-11-1989
			JP 55147272 A	17-11-1980
			JP 1117879 A	10-05-1989
			MC 1316 A	10-03-1981
			NO 801024 A	13-10-1980
			NZ 193316 A	31-07-1984
			PH 17987 A	28-02-1985
			PT 71078 A ,B	01-05-1980
			US 4352792 A	05-10-1982
			ZA 8002139 A	29-04-1981
			ZW 8180 A1	05-11-1980
EP 373986	A	20-06-1990	FR 2639830 A1	08-06-1990
			AT 94072 T	15-09-1993
			DE 68909019 D1	14-10-1993

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 00/01039

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 373986	A		DE 68909019 T2 DK 608089 A EP 0373986 A1 ES 2059803 T3 IL 92523 A JP 2034784 C JP 2184632 A JP 7037393 B	17-03-1994 03-06-1990 20-06-1990 16-11-1994 30-05-1994 28-03-1996 19-07-1990 26-04-1995
EP 861662	A	02-09-1998	US 5840278 A EP 0861662 A1	24-11-1998 02-09-1998
WO 9846238	A	22-10-1998	AU 7124398 A WO 9846238 A1	11-11-1998 22-10-1998
WO 9214458	A	03-09-1992	US 5449794 A AT 148341 T AU 668348 B2 AU 1277992 A CA 2104114 A1 DE 69217206 D1 DE 69217206 T2 DK 571491 T3 EP 0499015 A1 EP 0571491 A1 EP 0707851 A2 ES 2100335 T3 JP 6508103 T NZ 241633 A WO 9214458 A1 US 5591771 A US 5861430 A	12-09-1995 15-02-1997 02-05-1996 15-09-1992 16-08-1992 13-03-1997 28-08-1997 11-08-1997 19-08-1992 01-12-1993 24-04-1996 16-06-1997 14-09-1994 27-06-1994 03-09-1992 07-01-1997 19-01-1999
WO 9842188	A	01-10-1998	AU 727339 B2 AU 6771898 A BR 9807892 A CN 1258191 T EE 9900436 A EP 0980203 A1 HU 0001379 A2 JP 2000119188 A NO 994639 A PL 336168 A1 SK 131899 A3 TR 9902674 T2 WO 9842188 A1	07-12-2000 20-10-1998 22-02-2000 28-06-2000 17-04-2000 23-02-2000 28-08-2000 25-04-2000 24-11-1999 05-06-2000 11-12-2000 21-02-2000 01-10-1998
WO 9944578	A	10-09-1999	DE 19809304 A1 WO 9944578 A1 EP 1059911 A1	09-09-1999 10-09-1999 20-12-2000
WO 0032201	A	08-06-2000	AU 1745300 A BR 9915623 A EP 1135138 A2 WO 0032201 A2 AU 1923500 A AU 3105200 A BR 9915644 A	19-06-2000 14-08-2001 26-09-2001 08-06-2000 19-06-2000 19-06-2000 07-08-2001

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 00/01039

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0032201	A		EP 1133287 A2 WO 0032176 A2 WO 0032177 A2 AU 3919000 A WO 0056757 A1	19-09-2001 08-06-2000 08-06-2000 09-10-2000 28-09-2000
WO 9949862	A	07-10-1999	AU 3456499 A WO 9949862 A1	18-10-1999 07-10-1999
WO 0032177	A	08-06-2000	AU 3105200 A BR 9915644 A EP 1133287 A2 WO 0032177 A2 AU 1745300 A AU 1923500 A BR 9915623 A EP 1135138 A2 WO 0032201 A2 WO 0032176 A2 AU 3919000 A WO 0056757 A1	19-06-2000 07-08-2001 19-09-2001 08-06-2000 19-06-2000 19-06-2000 14-08-2001 26-09-2001 08-06-2000 08-06-2000 09-10-2000 28-09-2000
JP 9227373	A	02-09-1997	NONE	
JP 7002826	A	06-01-1995	NONE	
RO 114410	B	30-04-1999	NONE	
RO 75776	A	01-02-1983	RO 75776 A2	01-02-1983
JP 07277969	A	24-10-1995	NONE	
JP 3007224	A	14-01-1991	JP 1855394 C JP 5077649 B	07-07-1994 27-10-1993
JP 04018019	A	22-01-1992	JP 2974370 B2	10-11-1999
JP 02101013	A	12-04-1990	JP 2729638 B2	18-03-1998
JP 6199697	A	19-07-1994	NONE	

THIS PAGE BLANK (USPTO)